HUE025416T2 - Szubsztituált n-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-karboxamid vegyületek mint III-as típusú receptor tirozin-kináz inhibitorok - Google Patents
Szubsztituált n-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-karboxamid vegyületek mint III-as típusú receptor tirozin-kináz inhibitorok Download PDFInfo
- Publication number
- HUE025416T2 HUE025416T2 HUE11808427A HUE11808427A HUE025416T2 HU E025416 T2 HUE025416 T2 HU E025416T2 HU E11808427 A HUE11808427 A HU E11808427A HU E11808427 A HUE11808427 A HU E11808427A HU E025416 T2 HUE025416 T2 HU E025416T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- carboxamide
- indazol
- formula
- compound
- Prior art date
Links
- AYAOSDNSSUARDZ-UHFFFAOYSA-N n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide Chemical class C1=CC=CN2C(C(NC=3C=4C=NNC=4C=CC=3)=O)=CN=C21 AYAOSDNSSUARDZ-UHFFFAOYSA-N 0.000 title description 3
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 317
- 150000001875 compounds Chemical class 0.000 claims description 310
- 125000000217 alkyl group Chemical group 0.000 claims description 250
- 125000003545 alkoxy group Chemical group 0.000 claims description 163
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
- -1 alkoxy halogen Chemical class 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 79
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 75
- 125000001424 substituent group Chemical group 0.000 claims description 74
- 229920006395 saturated elastomer Polymers 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 53
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 35
- 239000002585 base Substances 0.000 claims description 33
- 208000002193 Pain Diseases 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 30
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 28
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 28
- 208000023275 Autoimmune disease Diseases 0.000 claims description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 208000027866 inflammatory disease Diseases 0.000 claims description 27
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 18
- 230000008878 coupling Effects 0.000 claims description 17
- 238000010168 coupling process Methods 0.000 claims description 17
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 229910052763 palladium Inorganic materials 0.000 claims description 8
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 125000006413 ring segment Chemical group 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007822 coupling agent Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000007800 oxidant agent Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 12
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 3
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 claims 3
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 101100450580 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) hepA gene Proteins 0.000 claims 2
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 claims 2
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 claims 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 claims 1
- BZUZJVLPAKJIBP-UHFFFAOYSA-N 6-amino-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical group O=C1N=C(N)N=C2NNC=C21 BZUZJVLPAKJIBP-UHFFFAOYSA-N 0.000 claims 1
- 241001666377 Apera Species 0.000 claims 1
- 241000972773 Aulopiformes Species 0.000 claims 1
- 101000693444 Homo sapiens Zinc transporter ZIP2 Proteins 0.000 claims 1
- 101100243947 Mus musculus Pidd1 gene Proteins 0.000 claims 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- 101100478330 Rattus norvegicus Srgn gene Proteins 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 102100025451 Zinc transporter ZIP2 Human genes 0.000 claims 1
- VEXNFKCQMGMBBJ-UHFFFAOYSA-N [1-(dimethylamino)-2-[(dimethylamino)methyl]butan-2-yl] benzoate Chemical compound CN(C)CC(CC)(CN(C)C)OC(=O)C1=CC=CC=C1 VEXNFKCQMGMBBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000013405 beer Nutrition 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000012971 dimethylpiperazine Substances 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- RIZMRRKBZQXFOY-UHFFFAOYSA-N ethion Chemical compound CCOP(=S)(OCC)SCSP(=S)(OCC)OCC RIZMRRKBZQXFOY-UHFFFAOYSA-N 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims 1
- DDNJSIOWWRSXGR-UHFFFAOYSA-N s-[3-carbamoylsulfanyl-2-(dimethylamino)propyl] carbamothioate;1,2,3,4,5,6-hexachlorocyclohexane;hydrochloride Chemical compound Cl.ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl.NC(=O)SCC(N(C)C)CSC(N)=O DDNJSIOWWRSXGR-UHFFFAOYSA-N 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 238000009938 salting Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 352
- 239000000203 mixture Substances 0.000 description 271
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 218
- 238000002360 preparation method Methods 0.000 description 203
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 162
- 235000019439 ethyl acetate Nutrition 0.000 description 153
- 239000007787 solid Substances 0.000 description 144
- 239000000243 solution Substances 0.000 description 138
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 111
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 101
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- 238000000034 method Methods 0.000 description 96
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 94
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 91
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 86
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 81
- 239000011541 reaction mixture Substances 0.000 description 75
- 201000010099 disease Diseases 0.000 description 70
- 239000000047 product Substances 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- 230000002829 reductive effect Effects 0.000 description 54
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 53
- 239000012267 brine Substances 0.000 description 47
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 47
- 239000000284 extract Substances 0.000 description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 46
- 238000003756 stirring Methods 0.000 description 43
- 229910052938 sodium sulfate Inorganic materials 0.000 description 40
- 235000011152 sodium sulphate Nutrition 0.000 description 40
- 210000000988 bone and bone Anatomy 0.000 description 38
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 37
- 238000004440 column chromatography Methods 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- 239000012043 crude product Substances 0.000 description 31
- 239000000706 filtrate Substances 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 239000000377 silicon dioxide Substances 0.000 description 29
- 206010016654 Fibrosis Diseases 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 230000004761 fibrosis Effects 0.000 description 26
- 239000012071 phase Substances 0.000 description 26
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 26
- PRHTYYZBWSGPSI-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=C(F)C=C1F PRHTYYZBWSGPSI-UHFFFAOYSA-N 0.000 description 25
- 125000004432 carbon atom Chemical group C* 0.000 description 25
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 24
- 238000012746 preparative thin layer chromatography Methods 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 229960004756 ethanol Drugs 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 22
- 238000001914 filtration Methods 0.000 description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 210000002540 macrophage Anatomy 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000013058 crude material Substances 0.000 description 18
- 239000003480 eluent Substances 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 229960001866 silicon dioxide Drugs 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 229940093956 potassium carbonate Drugs 0.000 description 15
- 235000011181 potassium carbonates Nutrition 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 13
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 13
- 239000005457 ice water Substances 0.000 description 13
- GUTJGRXTAAMNBO-UHFFFAOYSA-N 1-benzylindazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=CC=C1 GUTJGRXTAAMNBO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 208000003076 Osteolysis Diseases 0.000 description 12
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- AOTAXYVEONHYHY-UHFFFAOYSA-N 3-iodo-4-nitro-2h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(I)=NN2 AOTAXYVEONHYHY-UHFFFAOYSA-N 0.000 description 11
- XRULWYQXUUVBAD-UHFFFAOYSA-N 7-fluoro-n-[3-methyl-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(F)=CC5=NC=4)=C3C(C)=N2)=N1 XRULWYQXUUVBAD-UHFFFAOYSA-N 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 150000002170 ethers Chemical class 0.000 description 11
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 11
- 210000002997 osteoclast Anatomy 0.000 description 11
- 229920001296 polysiloxane Polymers 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 10
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 10
- 239000000010 aprotic solvent Substances 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 9
- FPEYDBWXOQJGJH-UHFFFAOYSA-N 3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-amine Chemical compound C12=CC=CC(N)=C2C(C)=NN1CC1=CC=CC(C)=N1 FPEYDBWXOQJGJH-UHFFFAOYSA-N 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 8
- KQLVTYYXXCUYML-UHFFFAOYSA-N 7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=C(OCCOC)C=CN2C(C(O)=O)=CN=C21 KQLVTYYXXCUYML-UHFFFAOYSA-N 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 208000028389 Nerve injury Diseases 0.000 description 8
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 8
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 8
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 8
- 230000008764 nerve damage Effects 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 7
- YQHJFPFNGVDEDT-UHFFFAOYSA-N 2-tert-butyl-1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(N(C)C)=NC(C)(C)C YQHJFPFNGVDEDT-UHFFFAOYSA-N 0.000 description 7
- YLDBIHFIYZJAHL-UHFFFAOYSA-N 7-bromo-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(Br)=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 YLDBIHFIYZJAHL-UHFFFAOYSA-N 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- BYZTUEFZDFUKGN-UHFFFAOYSA-N 2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethanol Chemical compound C1N(CCO)CC11COC1 BYZTUEFZDFUKGN-UHFFFAOYSA-N 0.000 description 6
- NOKZJLOSYWZYLU-UHFFFAOYSA-N 2-(chloromethyl)-6-propan-2-ylpyridine;hydrochloride Chemical compound Cl.CC(C)C1=CC=CC(CCl)=N1 NOKZJLOSYWZYLU-UHFFFAOYSA-N 0.000 description 6
- IPPKNEOMVCVEPJ-QMMMGPOBSA-N 2-[(3s)-3,4-dimethylpiperazin-1-yl]ethanol Chemical compound C[C@H]1CN(CCO)CCN1C IPPKNEOMVCVEPJ-QMMMGPOBSA-N 0.000 description 6
- FDWIEDCIZZLNEA-UHFFFAOYSA-N 3-(bromomethyl)-1-methylpyridin-2-one Chemical compound CN1C=CC=C(CBr)C1=O FDWIEDCIZZLNEA-UHFFFAOYSA-N 0.000 description 6
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 235000019502 Orange oil Nutrition 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 6
- 229910017051 nitrogen difluoride Inorganic materials 0.000 description 6
- 239000010502 orange oil Substances 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- UAAVSPMFBVFLKV-UHFFFAOYSA-N 1-benzyl-5-chloroindazol-4-amine Chemical compound N1=CC=2C(N)=C(Cl)C=CC=2N1CC1=CC=CC=C1 UAAVSPMFBVFLKV-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- DQEAEWALMCERGC-UHFFFAOYSA-N 3-methyl-4-nitro-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazole Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(=C3C(C)=N2)[N+]([O-])=O)=N1 DQEAEWALMCERGC-UHFFFAOYSA-N 0.000 description 5
- WBTVZVUYPVQEIF-UHFFFAOYSA-N 4-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C=NN2 WBTVZVUYPVQEIF-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 206010029240 Neuritis Diseases 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 150000008041 alkali metal carbonates Chemical class 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- LYBSMLJAHWGBLA-UHFFFAOYSA-N ethyl 7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CN2C(C(=O)OCC)=CN=C2C=C1OCCN1CCN(C)CC1 LYBSMLJAHWGBLA-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XFTPOEOFAGRNSM-UHFFFAOYSA-N tert-butyl 6-(2-hydroxyethyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical group C1N(C(=O)OC(C)(C)C)CC11CN(CCO)C1 XFTPOEOFAGRNSM-UHFFFAOYSA-N 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- PWSHDKJRJTWMGD-UHFFFAOYSA-N 3-iodo-1-[(6-methylpyridin-2-yl)methyl]-4-nitroindazole Chemical compound CC1=CC=CC(CN2C3=CC=CC(=C3C(I)=N2)[N+]([O-])=O)=N1 PWSHDKJRJTWMGD-UHFFFAOYSA-N 0.000 description 4
- UKXAXKQYJOEJHK-UHFFFAOYSA-N 7-fluoro-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(F)=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 UKXAXKQYJOEJHK-UHFFFAOYSA-N 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- VSMXICNMVNSRPH-UHFFFAOYSA-N ethyl 6-propan-2-ylpyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(C(C)C)=N1 VSMXICNMVNSRPH-UHFFFAOYSA-N 0.000 description 4
- YJISWZLKSURKFM-UHFFFAOYSA-N ethyl 7-fluoroimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(F)C=CN2C(C(=O)OCC)=CN=C21 YJISWZLKSURKFM-UHFFFAOYSA-N 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- MUWAMBRABFRDCP-UHFFFAOYSA-M lithium;7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxylate Chemical compound [Li+].C1CN(C)CCN1CCOC1=CC2=NC=C(C([O-])=O)N2C=C1 MUWAMBRABFRDCP-UHFFFAOYSA-M 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- LWJMZPAMYNTNFE-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-(2-oxoethyl)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(CC=O)=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 LWJMZPAMYNTNFE-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- VNYBCCNBKXOXGE-UHFFFAOYSA-M potassium;2-chloro-3-ethoxy-3-oxoprop-1-en-1-olate Chemical compound [K+].CCOC(=O)C(Cl)=C[O-] VNYBCCNBKXOXGE-UHFFFAOYSA-M 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VIUIAFNUKMJWFD-UHFFFAOYSA-N tert-butyl n-(4-fluoropyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(F)=CC=N1 VIUIAFNUKMJWFD-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- LHUBRVMTPXHRSE-UHFFFAOYSA-N 1-benzyl-3-methylindazol-4-amine Chemical compound C12=CC=CC(N)=C2C(C)=NN1CC1=CC=CC=C1 LHUBRVMTPXHRSE-UHFFFAOYSA-N 0.000 description 3
- XLRNKDOWFAWISQ-UHFFFAOYSA-N 1-benzyl-5,7-dichloroindazol-4-amine Chemical compound N1=CC=2C(N)=C(Cl)C=C(Cl)C=2N1CC1=CC=CC=C1 XLRNKDOWFAWISQ-UHFFFAOYSA-N 0.000 description 3
- KFWQFIPMBVSQTP-UHFFFAOYSA-N 1-benzyl-5-bromoindazol-4-amine Chemical compound N1=CC=2C(N)=C(Br)C=CC=2N1CC1=CC=CC=C1 KFWQFIPMBVSQTP-UHFFFAOYSA-N 0.000 description 3
- XLYNASJATMXPSJ-UHFFFAOYSA-N 1-phenylindazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1C1=CC=CC=C1 XLYNASJATMXPSJ-UHFFFAOYSA-N 0.000 description 3
- HYSZWUPCSXTPSX-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)ethanol Chemical compound CCN1CCN(CCO)CC1 HYSZWUPCSXTPSX-UHFFFAOYSA-N 0.000 description 3
- KDYNMWFSJAIPSW-UHFFFAOYSA-N 2-(4-propan-2-ylpiperazin-1-yl)ethanol Chemical group CC(C)N1CCN(CCO)CC1 KDYNMWFSJAIPSW-UHFFFAOYSA-N 0.000 description 3
- GMXPFOHILYTASS-UHFFFAOYSA-N 3-bromo-4-nitro-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazole Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(=C3C(Br)=N2)[N+]([O-])=O)=N1 GMXPFOHILYTASS-UHFFFAOYSA-N 0.000 description 3
- NQLBVAOIHLUCJK-UHFFFAOYSA-N 3-methyl-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazol-4-amine Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(N)=C3C(C)=N2)=N1 NQLBVAOIHLUCJK-UHFFFAOYSA-N 0.000 description 3
- IBVDAEMIEZJBSW-UHFFFAOYSA-N 3-methyl-4-nitro-2h-indazole Chemical compound C1=CC([N+]([O-])=O)=C2C(C)=NNC2=C1 IBVDAEMIEZJBSW-UHFFFAOYSA-N 0.000 description 3
- RWGVAUJAGXRGRF-UHFFFAOYSA-N 4-(2-morpholin-4-ylethoxy)pyridin-2-amine Chemical compound C1=NC(N)=CC(OCCN2CCOCC2)=C1 RWGVAUJAGXRGRF-UHFFFAOYSA-N 0.000 description 3
- WCCFLOQQACDOAX-UHFFFAOYSA-N 4-fluoropyridin-2-amine Chemical compound NC1=CC(F)=CC=N1 WCCFLOQQACDOAX-UHFFFAOYSA-N 0.000 description 3
- ORBGFFZSQHWHCJ-UHFFFAOYSA-N 4-nitro-1-(piperidin-3-ylmethyl)indazole Chemical compound N1=CC=2C([N+](=O)[O-])=CC=CC=2N1CC1CCCNC1 ORBGFFZSQHWHCJ-UHFFFAOYSA-N 0.000 description 3
- ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 description 3
- VPJJVXVLGDVRMM-UHFFFAOYSA-N 7-acetyl-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(C(=O)C)C=CN2C=1C(=O)NC(C=1C(C)=N2)=CC=CC=1N2CC1=CC=CC(C)=N1 VPJJVXVLGDVRMM-UHFFFAOYSA-N 0.000 description 3
- ULMCRJRVUODBOV-UHFFFAOYSA-N 7-fluoro-n-[3-methyl-1-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical group S1C(C(C)C)=NC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(F)=CC5=NC=4)=C3C(C)=N2)=C1 ULMCRJRVUODBOV-UHFFFAOYSA-N 0.000 description 3
- DEZSHNQMIWONQE-UHFFFAOYSA-N 7-fluoroimidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=C(F)C=CN2C(C(=O)O)=CN=C21 DEZSHNQMIWONQE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229940050390 benzoate Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- ORSVWYSFUABOQU-UHFFFAOYSA-N ethyl 6-chloropyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(Cl)=N1 ORSVWYSFUABOQU-UHFFFAOYSA-N 0.000 description 3
- RXBWYMFMEWFCSR-UHFFFAOYSA-N ethyl 6-prop-1-en-2-ylpyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(C(C)=C)=N1 RXBWYMFMEWFCSR-UHFFFAOYSA-N 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- DOGXPDFZEQXZDS-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=CC=CN2C(C(=O)O)=CN=C21 DOGXPDFZEQXZDS-UHFFFAOYSA-N 0.000 description 3
- KLQXTWZHGPAFMD-UHFFFAOYSA-M lithium;7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound [Li+].C1=CN2C(C(=O)[O-])=CN=C2C=C1OCCN1CCOCC1 KLQXTWZHGPAFMD-UHFFFAOYSA-M 0.000 description 3
- FITANCORDURZOD-UHFFFAOYSA-N methyl 7-bromoimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(Br)C=CN2C(C(=O)OC)=CN=C21 FITANCORDURZOD-UHFFFAOYSA-N 0.000 description 3
- NSCSEDHQESTDHS-UHFFFAOYSA-N n-[1-[(6-cyclopropylpyridin-2-yl)methyl]-3-methylindazol-4-yl]-7-fluoroimidazo[1,2-a]pyridine-3-carboxamide Chemical group C12=CC=CC(NC(=O)C=3N4C=CC(F)=CC4=NC=3)=C2C(C)=NN1CC(N=1)=CC=CC=1C1CC1 NSCSEDHQESTDHS-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000000010 osteolytic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- YKLJDMCXKMIXBD-UHFFFAOYSA-M sodium;3-(2-dicyclohexylphosphanylphenyl)-2,4-dimethoxybenzenesulfonate Chemical compound [Na+].COC1=CC=C(S([O-])(=O)=O)C(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 YKLJDMCXKMIXBD-UHFFFAOYSA-M 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- HXKLBVUTALKXTB-UHFFFAOYSA-N (6-cyclopentylpyridin-2-yl)methanol Chemical group OCC1=CC=CC(C2CCCC2)=N1 HXKLBVUTALKXTB-UHFFFAOYSA-N 0.000 description 2
- VVLAGYGCPZFAQX-UHFFFAOYSA-N (6-ethoxypyridin-2-yl)methanol Chemical compound CCOC1=CC=CC(CO)=N1 VVLAGYGCPZFAQX-UHFFFAOYSA-N 0.000 description 2
- DJCJOWDAAZEMCI-UHFFFAOYSA-N (6-methylpyridin-3-yl)methanol Chemical compound CC1=CC=C(CO)C=N1 DJCJOWDAAZEMCI-UHFFFAOYSA-N 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- HPPLTNINIBJGPO-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=CN=C1 HPPLTNINIBJGPO-UHFFFAOYSA-N 0.000 description 2
- MZJFQGVPNWZKKS-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-4-nitroindazole Chemical compound N1=CC=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=C(F)C=C1F MZJFQGVPNWZKKS-UHFFFAOYSA-N 0.000 description 2
- IBFHADQAJVVDDL-UHFFFAOYSA-N 1-[(6-cyclopentylpyridin-2-yl)methyl]-3-methyl-4-nitroindazole Chemical compound C12=CC=CC([N+]([O-])=O)=C2C(C)=NN1CC(N=1)=CC=CC=1C1CCCC1 IBFHADQAJVVDDL-UHFFFAOYSA-N 0.000 description 2
- UQQXJEFBXVUREA-UHFFFAOYSA-N 1-[3-[(4-nitroindazol-1-yl)methyl]piperidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCCC1CN1C2=CC=CC([N+]([O-])=O)=C2C=N1 UQQXJEFBXVUREA-UHFFFAOYSA-N 0.000 description 2
- JFSMARSCUUCKRE-UHFFFAOYSA-N 1-[[3-(trifluoromethyl)phenyl]methyl]indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=CC(C(F)(F)F)=C1 JFSMARSCUUCKRE-UHFFFAOYSA-N 0.000 description 2
- CUWFKTMBEDKMHP-UHFFFAOYSA-N 1-benzyl-3-methyl-4-nitroindazole Chemical compound C12=CC=CC([N+]([O-])=O)=C2C(C)=NN1CC1=CC=CC=C1 CUWFKTMBEDKMHP-UHFFFAOYSA-N 0.000 description 2
- IJUNZKOKAXJGRQ-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one Chemical compound C1=CC(=O)N(C)C=C1B1OC(C)(C)C(C)(C)O1 IJUNZKOKAXJGRQ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 2
- LCLXKLCMJTUIRQ-UHFFFAOYSA-N 2-(chloromethyl)-5-(trifluoromethyl)pyridine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=C(CCl)N=C1 LCLXKLCMJTUIRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IPPKNEOMVCVEPJ-MRVPVSSYSA-N 2-[(3r)-3,4-dimethylpiperazin-1-yl]ethanol Chemical compound C[C@@H]1CN(CCO)CCN1C IPPKNEOMVCVEPJ-MRVPVSSYSA-N 0.000 description 2
- RQINYFYGGDEZDI-UHFFFAOYSA-N 2-bromo-6-cyclopentylpyridine Chemical compound BrC1=CC=CC(C2CCCC2)=N1 RQINYFYGGDEZDI-UHFFFAOYSA-N 0.000 description 2
- FGSAQRJRWCZLOB-UHFFFAOYSA-N 2-chloro-4-fluoropyridine Chemical compound FC1=CC=NC(Cl)=C1 FGSAQRJRWCZLOB-UHFFFAOYSA-N 0.000 description 2
- VGDNZKQPMWBLAQ-UHFFFAOYSA-N 3-[(3-iodo-4-nitroindazol-1-yl)methyl]-1-methylpyridin-2-one Chemical compound O=C1N(C)C=CC=C1CN1C2=CC=CC([N+]([O-])=O)=C2C(I)=N1 VGDNZKQPMWBLAQ-UHFFFAOYSA-N 0.000 description 2
- MOUAWMUOFJADGU-UHFFFAOYSA-N 3-[(4-aminoindazol-1-yl)methyl]-1-methylpyridin-2-one Chemical compound O=C1N(C)C=CC=C1CN1C2=CC=CC(N)=C2C=N1 MOUAWMUOFJADGU-UHFFFAOYSA-N 0.000 description 2
- BKYFEBHLYKLAJH-UHFFFAOYSA-N 3-bromo-4-nitro-2h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=NNC(Br)=C12 BKYFEBHLYKLAJH-UHFFFAOYSA-N 0.000 description 2
- ADJNNPPEJZQSQJ-UHFFFAOYSA-N 3-iodo-4-nitro-1-(2-pyridin-2-ylethyl)indazole Chemical compound N1=C(I)C=2C([N+](=O)[O-])=CC=CC=2N1CCC1=CC=CC=N1 ADJNNPPEJZQSQJ-UHFFFAOYSA-N 0.000 description 2
- KAEJVRJIBRCKKZ-UHFFFAOYSA-N 3-iodo-4-nitro-1-[[3-(trifluoromethyl)phenyl]methyl]indazole Chemical compound N1=C(I)C=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=CC(C(F)(F)F)=C1 KAEJVRJIBRCKKZ-UHFFFAOYSA-N 0.000 description 2
- YJNBFMUJSMAAJP-UHFFFAOYSA-N 3-iodo-4-nitro-1-[[5-(trifluoromethyl)pyridin-2-yl]methyl]indazole Chemical compound N1=C(I)C=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=C(C(F)(F)F)C=N1 YJNBFMUJSMAAJP-UHFFFAOYSA-N 0.000 description 2
- OXYIHRSZXWMHPH-UHFFFAOYSA-N 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CC=NC(N)=C1 OXYIHRSZXWMHPH-UHFFFAOYSA-N 0.000 description 2
- PNXTVUMTJSABFR-UHFFFAOYSA-N 4-nitro-1-phenylindazole Chemical compound N1=CC=2C([N+](=O)[O-])=CC=CC=2N1C1=CC=CC=C1 PNXTVUMTJSABFR-UHFFFAOYSA-N 0.000 description 2
- GVMVLNGLIOYALD-UHFFFAOYSA-N 5-(chloromethyl)-2-methylpyridine;hydrochloride Chemical compound Cl.CC1=CC=C(CCl)C=N1 GVMVLNGLIOYALD-UHFFFAOYSA-N 0.000 description 2
- UVDJYBXHNFJTME-UHFFFAOYSA-N 6-bromo-5-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)C(Br)=N1 UVDJYBXHNFJTME-UHFFFAOYSA-N 0.000 description 2
- OEBPATOPDYFHIV-UHFFFAOYSA-N 6-cyclopropylpyridine-2-carbaldehyde Chemical compound O=CC1=CC=CC(C2CC2)=N1 OEBPATOPDYFHIV-UHFFFAOYSA-N 0.000 description 2
- KDGOODJXLHNGMS-UHFFFAOYSA-N 6-propan-2-ylpyridine-2-carboxylic acid Chemical compound CC(C)C1=CC=CC(C(O)=O)=N1 KDGOODJXLHNGMS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001137251 Corvidae Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 2
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 2
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 2
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 2
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 2
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 2
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 2
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 2
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 2
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 2
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 2
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 2
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- GVAFEGOUIQFLQH-UHFFFAOYSA-N [5-(trifluoromethyl)pyridin-2-yl]methanol Chemical group OCC1=CC=C(C(F)(F)F)C=N1 GVAFEGOUIQFLQH-UHFFFAOYSA-N 0.000 description 2
- 125000006241 alcohol protecting group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001723 carbon free-radicals Chemical class 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940124446 critical care medicine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- OYQVQWIASIXXRT-UHFFFAOYSA-N ethyl 2,4-dioxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)=O OYQVQWIASIXXRT-UHFFFAOYSA-N 0.000 description 2
- XOJOQIUVANMZEP-UHFFFAOYSA-N ethyl 5-methyl-1-propan-2-ylpyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C)N(C(C)C)N=1 XOJOQIUVANMZEP-UHFFFAOYSA-N 0.000 description 2
- OIYPCPPSPSTGIG-UHFFFAOYSA-N ethyl 6-cyanoimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CC(C#N)=CN2C(C(=O)OCC)=CN=C21 OIYPCPPSPSTGIG-UHFFFAOYSA-N 0.000 description 2
- LEKWWVNHYUXVAW-UHFFFAOYSA-N ethyl 6-ethoxypyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(OCC)=N1 LEKWWVNHYUXVAW-UHFFFAOYSA-N 0.000 description 2
- YTTUHWYNAVAFMP-UHFFFAOYSA-N ethyl 7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CN2C(C(=O)OCC)=CN=C2C=C1OCCN1CCOCC1 YTTUHWYNAVAFMP-UHFFFAOYSA-N 0.000 description 2
- CGPUGKFNICFYAU-UHFFFAOYSA-N ethyl 7-(ethoxymethoxy)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(OCOCC)C=CN2C(C(=O)OCC)=CN=C21 CGPUGKFNICFYAU-UHFFFAOYSA-N 0.000 description 2
- RGILLICMLOJOGQ-UHFFFAOYSA-N ethyl 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CN2C(C(=O)OCC)=CN=C2C=C1OCC1COC(C)(C)O1 RGILLICMLOJOGQ-UHFFFAOYSA-N 0.000 description 2
- XYRXFWMCGMXZTD-UHFFFAOYSA-N ethyl 7-[2-(4-propan-2-ylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CN2C(C(=O)OCC)=CN=C2C=C1OCCN1CCN(C(C)C)CC1 XYRXFWMCGMXZTD-UHFFFAOYSA-N 0.000 description 2
- GLOGJCLLWWVPHE-UHFFFAOYSA-N ethyl 7-[2-(dimethylamino)ethoxy]imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(OCCN(C)C)C=CN2C(C(=O)OCC)=CN=C21 GLOGJCLLWWVPHE-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- GBPKRPWLIIYJSV-UHFFFAOYSA-M lithium;6-cyanoimidazo[1,2-a]pyridine-3-carboxylate Chemical compound [Li+].C1=CC(C#N)=CN2C(C(=O)[O-])=CN=C21 GBPKRPWLIIYJSV-UHFFFAOYSA-M 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 2
- JBZCKKRMWILFJW-UHFFFAOYSA-N methyl 3-[(3-iodo-4-nitroindazol-1-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=CC(=C3C(I)=N2)[N+]([O-])=O)=C1 JBZCKKRMWILFJW-UHFFFAOYSA-N 0.000 description 2
- VSAHHNFBEGJLEX-UHFFFAOYSA-N methyl 6-fluoro-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=C(C)C([N+]([O-])=O)=CC=C1F VSAHHNFBEGJLEX-UHFFFAOYSA-N 0.000 description 2
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- WQCDPDQOGSMSBW-QFIPXVFZSA-N n-[1-[(6-cyclopropylpyridin-2-yl)methyl]-3-methylindazol-4-yl]-7-[2-[(3s)-3,4-dimethylpiperazin-1-yl]ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)[C@@H](C)CN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C)=NN(CC=5N=C(C=CC=5)C5CC5)C=4C=CC=3)N2C=C1 WQCDPDQOGSMSBW-QFIPXVFZSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 235000015108 pies Nutrition 0.000 description 2
- 208000007420 pigmented villonodular synovitis Diseases 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 210000001738 temporomandibular joint Anatomy 0.000 description 2
- XKLDSRDAJRHFIY-AOOOYVTPSA-N tert-butyl (3r,5s)-3,4,5-trimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)N1C XKLDSRDAJRHFIY-AOOOYVTPSA-N 0.000 description 2
- DSLKEBSGOWIHAT-UHFFFAOYSA-N tert-butyl 3-[(4-nitroindazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1CN1C2=CC=CC([N+]([O-])=O)=C2C=N1 DSLKEBSGOWIHAT-UHFFFAOYSA-N 0.000 description 2
- VUPVNZAULPQRDB-UHFFFAOYSA-N tert-butyl 4-[3-[[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]carbamoyl]imidazo[1,2-a]pyridin-7-yl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(=CC4=NC=3)C=3CCN(CC=3)C(=O)OC(C)(C)C)=C2C(C)=NN1CC1=CC=CC(C)=N1 VUPVNZAULPQRDB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- DRSAHDPLRNPPMJ-UHFFFAOYSA-N (2-propan-2-yl-1,3-thiazol-4-yl)methanol Chemical group CC(C)C1=NC(CO)=CS1 DRSAHDPLRNPPMJ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FDTROTPXJOUASG-ILKKLZGPSA-N (2s)-1,2-dimethylpiperazine;dihydrochloride Chemical group Cl.Cl.C[C@H]1CNCCN1C FDTROTPXJOUASG-ILKKLZGPSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- QHVYJSBQXIIROJ-KNVOCYPGSA-N (2s,6r)-1,2,6-trimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1C QHVYJSBQXIIROJ-KNVOCYPGSA-N 0.000 description 1
- SZLULMXLBYGMPO-DTQHMAPFSA-N (2s,6r)-1,2,6-trimethylpiperazine;dihydrochloride Chemical group Cl.Cl.C[C@H]1CNC[C@@H](C)N1C SZLULMXLBYGMPO-DTQHMAPFSA-N 0.000 description 1
- KIUPCUCGVCGPPA-UHFFFAOYSA-N (5-methyl-2-propan-2-ylcyclohexyl) carbonochloridate Chemical compound CC(C)C1CCC(C)CC1OC(Cl)=O KIUPCUCGVCGPPA-UHFFFAOYSA-N 0.000 description 1
- ZJKWKXNJLHDXRB-UHFFFAOYSA-N (5-propan-2-ylpyridin-2-yl)methanol Chemical compound CC(C)C1=CC=C(CO)N=C1 ZJKWKXNJLHDXRB-UHFFFAOYSA-N 0.000 description 1
- FAGYAWVHXHWORP-UHFFFAOYSA-N (6-cyclopropylpyridin-2-yl)methanol Chemical group OCC1=CC=CC(C2CC2)=N1 FAGYAWVHXHWORP-UHFFFAOYSA-N 0.000 description 1
- MZUSCPDSQJSBSY-UHFFFAOYSA-N (6-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=N1 MZUSCPDSQJSBSY-UHFFFAOYSA-N 0.000 description 1
- ZTOVDWLNTBSBLC-UHFFFAOYSA-N (6-tert-butylpyridin-2-yl)methanol Chemical group CC(C)(C)C1=CC=CC(CO)=N1 ZTOVDWLNTBSBLC-UHFFFAOYSA-N 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- LHOPDIPOMHVFAD-UHFFFAOYSA-N 1,3-dimethylpyridin-2-one Chemical compound CC1=CC=CN(C)C1=O LHOPDIPOMHVFAD-UHFFFAOYSA-N 0.000 description 1
- MYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- KSWZRXTYZARYFE-UHFFFAOYSA-N 1-(cyclohexylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1CCCCC1 KSWZRXTYZARYFE-UHFFFAOYSA-N 0.000 description 1
- IFDRKGHFHOQTEA-UHFFFAOYSA-N 1-(cyclopropylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1CC1 IFDRKGHFHOQTEA-UHFFFAOYSA-N 0.000 description 1
- OPDUHQJNZIHEOE-UHFFFAOYSA-N 1-(oxan-2-ylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1CCCCO1 OPDUHQJNZIHEOE-UHFFFAOYSA-N 0.000 description 1
- DDLAOHFQPJYCBV-UHFFFAOYSA-N 1-(oxan-4-ylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1CCOCC1 DDLAOHFQPJYCBV-UHFFFAOYSA-N 0.000 description 1
- CTVDKVCXCQQPAK-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=CC=N1 CTVDKVCXCQQPAK-UHFFFAOYSA-N 0.000 description 1
- HGVAAXOOGHJCEL-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=NC=C1 HGVAAXOOGHJCEL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- LFHQAEJKMWUYAR-UHFFFAOYSA-N 1-[(2-methylpyridin-3-yl)methyl]indazol-4-amine Chemical compound CC1=NC=CC=C1CN1C2=CC=CC(N)=C2C=N1 LFHQAEJKMWUYAR-UHFFFAOYSA-N 0.000 description 1
- WOFHENVBEDHQIO-UHFFFAOYSA-N 1-[(3-phenylmethoxyphenyl)methyl]indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC(C=1)=CC=CC=1OCC1=CC=CC=C1 WOFHENVBEDHQIO-UHFFFAOYSA-N 0.000 description 1
- QNDWPEOCXHOOND-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]indazol-4-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=CC(N)=C2C=N1 QNDWPEOCXHOOND-UHFFFAOYSA-N 0.000 description 1
- QFHYERUNSOILFN-UHFFFAOYSA-N 1-[(6-methylpyridin-2-yl)methyl]indazol-4-amine Chemical compound CC1=CC=CC(CN2C3=CC=CC(N)=C3C=N2)=N1 QFHYERUNSOILFN-UHFFFAOYSA-N 0.000 description 1
- ZLFDKEHTVPUXGJ-UHFFFAOYSA-N 1-[(6-methylpyridin-3-yl)methyl]indazol-4-amine Chemical compound C1=NC(C)=CC=C1CN1C2=CC=CC(N)=C2C=N1 ZLFDKEHTVPUXGJ-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- DXYPFJIYGPRBSA-UHFFFAOYSA-N 1-[[4-(trifluoromethyl)phenyl]methyl]indazol-4-amine Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=C(C(F)(F)F)C=C1 DXYPFJIYGPRBSA-UHFFFAOYSA-N 0.000 description 1
- CORAVBWSIRXYHF-UHFFFAOYSA-N 1-benzyl-4-nitroindazole Chemical compound N1=CC=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=CC=C1 CORAVBWSIRXYHF-UHFFFAOYSA-N 0.000 description 1
- ANFSMPDYIOANAG-UHFFFAOYSA-N 1-benzyl-7-chloroindazol-4-amine Chemical compound N1=CC=2C(N)=CC=C(Cl)C=2N1CC1=CC=CC=C1 ANFSMPDYIOANAG-UHFFFAOYSA-N 0.000 description 1
- JUQWFONZRDXAAB-UHFFFAOYSA-N 1-methyl-1-oxidopiperazin-1-ium Chemical compound C[N+]1([O-])CCNCC1 JUQWFONZRDXAAB-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical group C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 1
- SAXTXIDZMKZQMV-UHFFFAOYSA-N 2-(2-bromoethyl)pyridin-1-ium;bromide Chemical compound Br.BrCCC1=CC=CC=N1 SAXTXIDZMKZQMV-UHFFFAOYSA-N 0.000 description 1
- LTEUPRATGSLSLD-UHFFFAOYSA-N 2-(3,3,4-trimethylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1(C)C LTEUPRATGSLSLD-UHFFFAOYSA-N 0.000 description 1
- AJZYETCLSRTJOY-UHFFFAOYSA-N 2-(4-methyl-1,4-diazepan-1-yl)ethanol Chemical compound CN1CCCN(CCO)CC1 AJZYETCLSRTJOY-UHFFFAOYSA-N 0.000 description 1
- AOGRBFZZIBBBPN-UHFFFAOYSA-N 2-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)ethanol Chemical group C1N(C)CC21CN(CCO)C2 AOGRBFZZIBBBPN-UHFFFAOYSA-N 0.000 description 1
- WJFDCFHWFHCLIW-UHFFFAOYSA-N 2-(bromomethyl)-6-methylpyridine Chemical compound CC1=CC=CC(CBr)=N1 WJFDCFHWFHCLIW-UHFFFAOYSA-N 0.000 description 1
- NQBCZKHYOFVAED-UHFFFAOYSA-N 2-(chloromethyl)-6-(trifluoromethyl)pyridine;hydrochloride Chemical group Cl.FC(F)(F)C1=CC=CC(CCl)=N1 NQBCZKHYOFVAED-UHFFFAOYSA-N 0.000 description 1
- HGVYVXAGWXPUQQ-UHFFFAOYSA-N 2-(chloromethyl)-6-cyclopropylpyridine;hydrochloride Chemical compound Cl.ClCC1=CC=CC(C2CC2)=N1 HGVYVXAGWXPUQQ-UHFFFAOYSA-N 0.000 description 1
- KIKOBYZTECEQQZ-UHFFFAOYSA-N 2-(chloromethyl)-6-ethoxypyridine;hydrochloride Chemical compound Cl.CCOC1=CC=CC(CCl)=N1 KIKOBYZTECEQQZ-UHFFFAOYSA-N 0.000 description 1
- BDLXTDLGTWNUFM-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]ethanol Chemical group CC(C)(C)OCCO BDLXTDLGTWNUFM-UHFFFAOYSA-N 0.000 description 1
- YAZZDLUHQQQWGQ-DTORHVGOSA-N 2-[(3s,5r)-3,4,5-trimethylpiperazin-1-yl]ethanol Chemical compound C[C@H]1CN(CCO)C[C@@H](C)N1C YAZZDLUHQQQWGQ-DTORHVGOSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PBGZUBFACSCIOG-UHFFFAOYSA-N 2-[4-(2-methoxyethyl)piperazin-1-yl]ethanol Chemical compound COCCN1CCN(CCO)CC1 PBGZUBFACSCIOG-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- HQNIMNQVKVPZES-UHFFFAOYSA-N 2-amino-1h-pyridin-4-one Chemical compound NC1=CC(O)=CC=N1 HQNIMNQVKVPZES-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- KKVUMKHUMBXLMH-UHFFFAOYSA-N 2-bromo-3-fluoro-6-methylpyridine Chemical compound CC1=CC=C(F)C(Br)=N1 KKVUMKHUMBXLMH-UHFFFAOYSA-N 0.000 description 1
- MHLLUSHSDFVJLE-UHFFFAOYSA-N 2-bromo-5-propylpyridine Chemical compound CCCC1=CC=C(Br)N=C1 MHLLUSHSDFVJLE-UHFFFAOYSA-N 0.000 description 1
- ZVQSZDKUCGKHQL-UHFFFAOYSA-N 2-bromo-6-cyclopropylpyridine Chemical compound BrC1=CC=CC(C2CC2)=N1 ZVQSZDKUCGKHQL-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- WFIFHOWQEJADPH-UHFFFAOYSA-N 2-chloro-4-(2-oxo-4-phenylpyrrolidin-1-yl)benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)C1 WFIFHOWQEJADPH-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- KOUVDKDABFOPIG-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane;oxalic acid Chemical group OC(=O)C(O)=O.C1NCC11COC1 KOUVDKDABFOPIG-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical group OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- YHLAYJXPNLUVRI-UHFFFAOYSA-N 2-tert-butyl-6-(chloromethyl)pyridine;hydrochloride Chemical group Cl.CC(C)(C)C1=CC=CC(CCl)=N1 YHLAYJXPNLUVRI-UHFFFAOYSA-N 0.000 description 1
- GNUDAJTUCJEBEI-UHFFFAOYSA-N 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound CC1=NNC(C)=C1B1OC(C)(C)C(C)(C)O1 GNUDAJTUCJEBEI-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical group C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- DLOCYNWDGKZBOL-UHFFFAOYSA-N 3-(chloromethyl)-1-propan-2-ylpyrazole;hydrochloride Chemical group Cl.CC(C)N1C=CC(CCl)=N1 DLOCYNWDGKZBOL-UHFFFAOYSA-N 0.000 description 1
- IAIVBMDMECTBOB-UHFFFAOYSA-N 3-(chloromethyl)-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(CCl)=C1 IAIVBMDMECTBOB-UHFFFAOYSA-N 0.000 description 1
- YCAIYRWHKSJKEB-UHFFFAOYSA-N 3-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=CC(C(Cl)=O)=C1 YCAIYRWHKSJKEB-UHFFFAOYSA-N 0.000 description 1
- VHXYJKLSWSBTDY-UHFFFAOYSA-N 3-[(3-iodo-4-nitroindazol-1-yl)methyl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(CN2C3=CC=CC(=C3C(I)=N2)[N+]([O-])=O)=C1 VHXYJKLSWSBTDY-UHFFFAOYSA-N 0.000 description 1
- BTKOYOSWRKPJCR-UHFFFAOYSA-N 3-[(3-iodo-4-nitroindazol-1-yl)methyl]benzonitrile Chemical compound N1=C(I)C=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=CC(C#N)=C1 BTKOYOSWRKPJCR-UHFFFAOYSA-N 0.000 description 1
- GFYRSHSWDZRSNF-UHFFFAOYSA-N 3-[(4-aminoindazol-1-yl)methyl]benzonitrile Chemical compound N1=CC=2C(N)=CC=CC=2N1CC1=CC=CC(C#N)=C1 GFYRSHSWDZRSNF-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- INPMLTPXUMDSSM-UHFFFAOYSA-N 3-chloro-1-[(6-cyclopropylpyridin-2-yl)methyl]-4-nitroindazole Chemical group N1=C(Cl)C=2C([N+](=O)[O-])=CC=CC=2N1CC(N=1)=CC=CC=1C1CC1 INPMLTPXUMDSSM-UHFFFAOYSA-N 0.000 description 1
- GUGAGLJJSMABRQ-UHFFFAOYSA-N 3-chloro-4-nitro-2h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(Cl)=NN2 GUGAGLJJSMABRQ-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- UVJPZZDDYGMWJC-UHFFFAOYSA-N 3-iodo-4-nitro-1-(pyridin-3-ylmethyl)indazole Chemical compound N1=C(I)C=2C([N+](=O)[O-])=CC=CC=2N1CC1=CC=CN=C1 UVJPZZDDYGMWJC-UHFFFAOYSA-N 0.000 description 1
- WZVFTOOGWGRSOU-UHFFFAOYSA-N 3-methyl-1-(oxan-4-ylmethyl)indazol-4-amine Chemical compound C12=CC=CC(N)=C2C(C)=NN1CC1CCOCC1 WZVFTOOGWGRSOU-UHFFFAOYSA-N 0.000 description 1
- WQFFQHYZYNMUSD-UHFFFAOYSA-N 3-methyl-1-[(5-methyl-1-propan-2-ylpyrazol-3-yl)methyl]-4-nitroindazole Chemical compound C1=C(C)N(C(C)C)N=C1CN1C2=CC=CC([N+]([O-])=O)=C2C(C)=N1 WQFFQHYZYNMUSD-UHFFFAOYSA-N 0.000 description 1
- QLVRWCFWIZPGEJ-UHFFFAOYSA-N 3-methyl-1-[(6-methylpyridin-3-yl)methyl]indazol-4-amine Chemical compound C12=CC=CC(N)=C2C(C)=NN1CC1=CC=C(C)N=C1 QLVRWCFWIZPGEJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VAJUUDUWDNCECT-UHFFFAOYSA-N 4-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=NC=C1 VAJUUDUWDNCECT-UHFFFAOYSA-N 0.000 description 1
- UFWPWAYADRYSBA-UHFFFAOYSA-N 4-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=NC(CCl)=C1 UFWPWAYADRYSBA-UHFFFAOYSA-N 0.000 description 1
- CSTGNMKKUNFVGV-UHFFFAOYSA-N 4-(chloromethyl)-2-propan-2-yl-1,3-thiazole;hydrochloride Chemical group Cl.CC(C)C1=NC(CCl)=CS1 CSTGNMKKUNFVGV-UHFFFAOYSA-N 0.000 description 1
- YSCJCEVEVDHTPE-UHFFFAOYSA-N 4-[(3-bromo-4-nitroindazol-1-yl)methyl]-2-propan-2-yl-1,3-thiazole Chemical compound S1C(C(C)C)=NC(CN2C3=CC=CC(=C3C(Br)=N2)[N+]([O-])=O)=C1 YSCJCEVEVDHTPE-UHFFFAOYSA-N 0.000 description 1
- WVXIDSOQIAHIMJ-UHFFFAOYSA-N 4-[2-(4-methylpiperazin-1-yl)ethoxy]pyridin-2-amine Chemical compound C1CN(C)CCN1CCOC1=CC=NC(N)=C1 WVXIDSOQIAHIMJ-UHFFFAOYSA-N 0.000 description 1
- FSJCNVHPCVGFEZ-UHFFFAOYSA-N 4-[2-(4-propan-2-ylpiperazin-1-yl)ethoxy]pyridin-2-amine Chemical compound C1CN(C(C)C)CCN1CCOC1=CC=NC(N)=C1 FSJCNVHPCVGFEZ-UHFFFAOYSA-N 0.000 description 1
- KLSUGDHMUHEALY-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]pyridin-2-amine Chemical compound CN(C)CCOC1=CC=NC(N)=C1 KLSUGDHMUHEALY-UHFFFAOYSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical group BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- QZSNYYBWMYGXOD-UHFFFAOYSA-N 5-chloro-1-[[3-(trifluoromethyl)phenyl]methyl]indazol-4-amine Chemical compound N1=CC=2C(N)=C(Cl)C=CC=2N1CC1=CC=CC(C(F)(F)F)=C1 QZSNYYBWMYGXOD-UHFFFAOYSA-N 0.000 description 1
- WOCOZBZKLXZCIZ-UHFFFAOYSA-N 5-prop-1-en-2-ylpyridine-2-carbaldehyde Chemical compound CC(=C)C1=CC=C(C=O)N=C1 WOCOZBZKLXZCIZ-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- VRCWSYYXUCKEED-UHFFFAOYSA-N 6-Hydroxypicolinic acid Chemical compound OC(=O)C1=CC=CC(=O)N1 VRCWSYYXUCKEED-UHFFFAOYSA-N 0.000 description 1
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 1
- XBNCEMAQEYTQHZ-UHFFFAOYSA-N 6-cyano-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=C(C=CC4=NC=3)C#N)=C2C(C)=NN1CC1=CC=CC(C)=N1 XBNCEMAQEYTQHZ-UHFFFAOYSA-N 0.000 description 1
- DEPIFWRMRCNBGQ-UHFFFAOYSA-N 6-fluoro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C([N+]([O-])=O)C=CC(F)=C1C(O)=O DEPIFWRMRCNBGQ-UHFFFAOYSA-N 0.000 description 1
- WEOQORGOLMAVLE-UHFFFAOYSA-N 6-tert-butylpyridine-2-carbaldehyde Chemical group CC(C)(C)C1=CC=CC(C=O)=N1 WEOQORGOLMAVLE-UHFFFAOYSA-N 0.000 description 1
- JXJDXQCZKIPGQE-UHFFFAOYSA-N 7-(2-methoxyethoxy)-n-[1-(piperidin-3-ylmethyl)indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C=N2)=CC=CC=1N2CC1CCCNC1 JXJDXQCZKIPGQE-UHFFFAOYSA-N 0.000 description 1
- BPMBQTKGXIXEIS-UHFFFAOYSA-N 7-(2-methoxyethoxy)-n-[1-(piperidin-4-ylmethyl)indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C=N2)=CC=CC=1N2CC1CCNCC1 BPMBQTKGXIXEIS-UHFFFAOYSA-N 0.000 description 1
- NBVSVINKCPUZOG-UHFFFAOYSA-N 7-(2-methoxyethoxy)-n-[1-[(3-phenylmethoxyphenyl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C=N2)=CC=CC=1N2CC(C=1)=CC=CC=1OCC1=CC=CC=C1 NBVSVINKCPUZOG-UHFFFAOYSA-N 0.000 description 1
- URUGPLVXPCDESZ-UHFFFAOYSA-N 7-(ethoxymethoxy)-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCOCC)C=CN2C=1C(=O)NC(C=1C(C)=N2)=CC=CC=1N2CC1=CC=CC(C)=N1 URUGPLVXPCDESZ-UHFFFAOYSA-N 0.000 description 1
- NYWKLBBPHXZAAE-UHFFFAOYSA-N 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]imidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound O1C(C)(C)OCC1COC1=CC2=NC=C(C(O)=O)N2C=C1 NYWKLBBPHXZAAE-UHFFFAOYSA-N 0.000 description 1
- OYAKJMUDCRUFMC-UHFFFAOYSA-N 7-[2-(4-methylpiperazin-1-yl)ethoxy]-n-[1-(pyridin-3-ylmethyl)indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C=NN(CC=5C=NC=CC=5)C=4C=CC=3)N2C=C1 OYAKJMUDCRUFMC-UHFFFAOYSA-N 0.000 description 1
- OFPCRSQSIGZFFB-UHFFFAOYSA-N 7-[2-(4-methylpiperazin-1-yl)ethoxy]-n-[1-[[5-(trifluoromethyl)pyridin-2-yl]methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C=NN(CC=5N=CC(=CC=5)C(F)(F)F)C=4C=CC=3)N2C=C1 OFPCRSQSIGZFFB-UHFFFAOYSA-N 0.000 description 1
- LSVIPIFEIZLAKH-UHFFFAOYSA-N 7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(O)=O)N2C=C1 LSVIPIFEIZLAKH-UHFFFAOYSA-N 0.000 description 1
- MWPOANXKDIXRKH-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCCN(C)C)C=CN2C=1C(=O)NC(C=1C(C)=N2)=CC=CC=1N2CC1=CC=CC(C)=N1 MWPOANXKDIXRKH-UHFFFAOYSA-N 0.000 description 1
- NNBDKJHKUYMGLT-UHFFFAOYSA-N 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=C(Br)C=CN2C(C(=O)O)=CN=C21 NNBDKJHKUYMGLT-UHFFFAOYSA-N 0.000 description 1
- OCQDWZGPMFUIRW-UHFFFAOYSA-N 7-chloro-1-[(6-methylpyridin-2-yl)methyl]indazol-4-amine Chemical compound CC1=CC=CC(CN2C3=C(Cl)C=CC(N)=C3C=N2)=N1 OCQDWZGPMFUIRW-UHFFFAOYSA-N 0.000 description 1
- DHSVGALRYCZRNJ-UHFFFAOYSA-N 7-chloro-n-[3-methyl-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(Cl)=CC5=NC=4)=C3C(C)=N2)=N1 DHSVGALRYCZRNJ-UHFFFAOYSA-N 0.000 description 1
- WDZDVGWOFKYQAB-UHFFFAOYSA-N 7-ethoxyimidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=C(OCC)C=CN2C(C(O)=O)=CN=C21 WDZDVGWOFKYQAB-UHFFFAOYSA-N 0.000 description 1
- JHCDELSCNPNANO-UHFFFAOYSA-N 7-fluoro-n-[3-methyl-1-[(5-methyl-1-propan-2-ylpyrazol-3-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical group C1=C(C)N(C(C)C)N=C1CN1C2=CC=CC(NC(=O)C=3N4C=CC(F)=CC4=NC=3)=C2C(C)=N1 JHCDELSCNPNANO-UHFFFAOYSA-N 0.000 description 1
- MSNJGLIZTIZCLS-UHFFFAOYSA-N 7-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid Chemical compound C1=C(OC)C=CN2C(C(O)=O)=CN=C21 MSNJGLIZTIZCLS-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical group C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HARVJGNBIPHBTA-UHFFFAOYSA-N C1=C(O)C=CN2C(C(=O)O)=CN=C21 Chemical compound C1=C(O)C=CN2C(C(=O)O)=CN=C21 HARVJGNBIPHBTA-UHFFFAOYSA-N 0.000 description 1
- FNCVPQBYHZMRRX-UHFFFAOYSA-N C1=C(O)C=CN2C(C(=O)OCC)=CN=C21 Chemical compound C1=C(O)C=CN2C(C(=O)OCC)=CN=C21 FNCVPQBYHZMRRX-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 206010034232 Pelvi-ureteric obstruction Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- OOSYBDIVLBCQCU-UHFFFAOYSA-N ethyl 1-propan-2-ylpyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=CN(C(C)C)N=1 OOSYBDIVLBCQCU-UHFFFAOYSA-N 0.000 description 1
- YIRIVXCQCCCFFI-UHFFFAOYSA-N ethyl 7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridine-3-carboxylate;4-(2-morpholin-4-ylethoxy)pyridin-2-amine Chemical compound C1=NC(N)=CC(OCCN2CCOCC2)=C1.C1=CN2C(C(=O)OCC)=CN=C2C=C1OCCN1CCOCC1 YIRIVXCQCCCFFI-UHFFFAOYSA-N 0.000 description 1
- PRZDNEWTCXZFFJ-UHFFFAOYSA-N ethyl 7-chloroimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(Cl)C=CN2C(C(=O)OCC)=CN=C21 PRZDNEWTCXZFFJ-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- KFDYOAOQSJVTBQ-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide dihydrochloride Chemical compound Cl.Cl.N=1C=C(N2C1C=CC=C2)C(=O)N KFDYOAOQSJVTBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- DXIDAMWLBJRSMC-UHFFFAOYSA-M lithium;7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxylic acid;chloride Chemical compound [Li+].[Cl-].C1CN(C)CCN1CCOC1=CC2=NC=C(C(O)=O)N2C=C1 DXIDAMWLBJRSMC-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IVNIWYRNWOKJRU-UHFFFAOYSA-N methyl 3-[(4-aminoindazol-1-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=CC(N)=C3C=N2)=C1 IVNIWYRNWOKJRU-UHFFFAOYSA-N 0.000 description 1
- BYIUEMZLFUYQSU-UHFFFAOYSA-N methyl 3-[[4-[[7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carbonyl]amino]indazol-1-yl]methyl]benzoate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C=N2)=CC=CC=1N2CC1=CC=CC(C(=O)OC)=C1 BYIUEMZLFUYQSU-UHFFFAOYSA-N 0.000 description 1
- YEQMIBAPFRZDLZ-UHFFFAOYSA-N methyl 3-[[4-[[7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carbonyl]amino]indazol-1-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(OCCN6CCN(C)CC6)=CC5=NC=4)=C3C=N2)=C1 YEQMIBAPFRZDLZ-UHFFFAOYSA-N 0.000 description 1
- GCLVXDCQEQNQOG-UHFFFAOYSA-N methyl 3-amino-6-fluoro-2-methylbenzoate Chemical compound COC(=O)C1=C(C)C(N)=CC=C1F GCLVXDCQEQNQOG-UHFFFAOYSA-N 0.000 description 1
- NEZIFEVPUMJKTF-UHFFFAOYSA-N methyl 7-(2-methylpyrazol-3-yl)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=CN2C(C(=O)OC)=CN=C2C=C1C1=CC=NN1C NEZIFEVPUMJKTF-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000011201 multicentric reticulohistiocytosis Diseases 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- IMNDHOCGZLYMRO-UHFFFAOYSA-N n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1 IMNDHOCGZLYMRO-UHFFFAOYSA-N 0.000 description 1
- MSZGXBOIMNUSNZ-UHFFFAOYSA-N n-(1-benzyl-3-methylindazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C(C)=N2)=CC=CC=1N2CC1=CC=CC=C1 MSZGXBOIMNUSNZ-UHFFFAOYSA-N 0.000 description 1
- CQCLOAMVKGCFEO-UHFFFAOYSA-N n-[1-[(1-methyl-2-oxopyridin-3-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C=NN(CC=5C(N(C)C=CC=5)=O)C=4C=CC=3)N2C=C1 CQCLOAMVKGCFEO-UHFFFAOYSA-N 0.000 description 1
- KYYSESRZYWNLAN-UHFFFAOYSA-N n-[1-[(3-hydroxyphenyl)methyl]indazol-4-yl]-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)NC(C=1C=N2)=CC=CC=1N2CC1=CC=CC(O)=C1 KYYSESRZYWNLAN-UHFFFAOYSA-N 0.000 description 1
- JHKYNHZASUKZBJ-UHFFFAOYSA-N n-[1-[[3-(dimethylcarbamoyl)phenyl]methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound CN(C)C(=O)C1=CC=CC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(OCCN6CCN(C)CC6)=CC5=NC=4)=C3C=N2)=C1 JHKYNHZASUKZBJ-UHFFFAOYSA-N 0.000 description 1
- NPNXMIVKNOQFGL-UHFFFAOYSA-N n-[3-chloro-1-[(6-cyclopropylpyridin-2-yl)methyl]indazol-4-yl]-7-fluoroimidazo[1,2-a]pyridine-3-carboxamide Chemical group C=1N=C2C=C(F)C=CN2C=1C(=O)NC(C=1C(Cl)=N2)=CC=CC=1N2CC(N=1)=CC=CC=1C1CC1 NPNXMIVKNOQFGL-UHFFFAOYSA-N 0.000 description 1
- XFSBRPJDGRZUAC-UHFFFAOYSA-N n-[3-ethyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-(2-oxoethyl)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(CC=O)=CC4=NC=3)=C2C(CC)=NN1CC1=CC=CC(C)=N1 XFSBRPJDGRZUAC-UHFFFAOYSA-N 0.000 description 1
- FIHVLAZBUUMFAB-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-(1-methyl-6-oxopyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(=CC4=NC=3)C3=CN(C)C(=O)C=C3)=C2C(C)=NN1CC1=CC=CC(C)=N1 FIHVLAZBUUMFAB-UHFFFAOYSA-N 0.000 description 1
- HEYHYGHEVDHRGQ-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(OCCN5CCOCC5)=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 HEYHYGHEVDHRGQ-UHFFFAOYSA-N 0.000 description 1
- CJYXYCBMCGQIPG-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C)=NN(CC=5N=C(C)C=CC=5)C=4C=CC=3)N2C=C1 CJYXYCBMCGQIPG-UHFFFAOYSA-N 0.000 description 1
- YZDQOULYSQYGJD-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-[(2-methylpropan-2-yl)oxy]ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC(OCCOC(C)(C)C)=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 YZDQOULYSQYGJD-UHFFFAOYSA-N 0.000 description 1
- UNEBOQFCIQVXLS-UHFFFAOYSA-N n-[3-methyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C12=CC=CC(NC(=O)C=3N4C=CC=CC4=NC=3)=C2C(C)=NN1CC1=CC=CC(C)=N1 UNEBOQFCIQVXLS-UHFFFAOYSA-N 0.000 description 1
- MEPILIDRHWLDAZ-UHFFFAOYSA-N n-[3-methyl-1-[(6-propan-2-ylpyridin-2-yl)methyl]indazol-4-yl]-7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridine-3-carboxamide Chemical compound CC(C)C1=CC=CC(CN2C3=CC=CC(NC(=O)C=4N5C=CC(OCCN6CCOCC6)=CC5=NC=4)=C3C(C)=N2)=N1 MEPILIDRHWLDAZ-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- VJMRDNJMLNLBQX-UHFFFAOYSA-N n-[7-chloro-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C=NN(CC=5N=C(C)C=CC=5)C=4C(Cl)=CC=3)N2C=C1 VJMRDNJMLNLBQX-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical class OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2r)-2-methylpiperazine-1-carboxylate Chemical group C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 1
- VBEKMNXJHBOWCT-SNVBAGLBSA-N tert-butyl (2r)-4-(2-hydroxyethyl)-2-methylpiperazine-1-carboxylate Chemical group C[C@@H]1CN(CCO)CCN1C(=O)OC(C)(C)C VBEKMNXJHBOWCT-SNVBAGLBSA-N 0.000 description 1
- FKAKHOACGNPXDZ-CYBMUJFWSA-N tert-butyl (3r)-3-[(4-aminoindazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1CN1C2=CC=CC(N)=C2C=N1 FKAKHOACGNPXDZ-CYBMUJFWSA-N 0.000 description 1
- IRQAVHKOEKPMFB-VIFPVBQESA-N tert-butyl (3s)-3,4-dimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1C IRQAVHKOEKPMFB-VIFPVBQESA-N 0.000 description 1
- NUZXPHIQZUYMOR-DTORHVGOSA-N tert-butyl (3s,5r)-3,5-dimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)N1 NUZXPHIQZUYMOR-DTORHVGOSA-N 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- DVMUNQAGXAMHOR-UHFFFAOYSA-N tert-butyl 2,2-dimethylpiperazine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCNCC1(C)C DVMUNQAGXAMHOR-UHFFFAOYSA-N 0.000 description 1
- PYRAMVPOMDHTNX-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate;oxalic acid Chemical group OC(=O)C(O)=O.C1N(C(=O)OC(C)(C)C)CC11CNC1.C1N(C(=O)OC(C)(C)C)CC11CNC1 PYRAMVPOMDHTNX-UHFFFAOYSA-N 0.000 description 1
- LSGFHZXBFSWQJS-UHFFFAOYSA-N tert-butyl 2-[(4-aminoindazol-1-yl)methyl]morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCOC1CN1C2=CC=CC(N)=C2C=N1 LSGFHZXBFSWQJS-UHFFFAOYSA-N 0.000 description 1
- FKAKHOACGNPXDZ-UHFFFAOYSA-N tert-butyl 3-[(4-aminoindazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1CN1C2=CC=CC(N)=C2C=N1 FKAKHOACGNPXDZ-UHFFFAOYSA-N 0.000 description 1
- GOCADJZGBKCYNV-UHFFFAOYSA-N tert-butyl 3-[(4-methylphenyl)sulfonyloxymethyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CN(C(=O)OC(C)(C)C)CCC1 GOCADJZGBKCYNV-UHFFFAOYSA-N 0.000 description 1
- AOVWADYIVQEBHV-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)-1,4-diazepane-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCCN(CCO)CC1 AOVWADYIVQEBHV-UHFFFAOYSA-N 0.000 description 1
- FSOCMTWSSASREE-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)-2,2-dimethylpiperazine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCN(CCO)CC1(C)C FSOCMTWSSASREE-UHFFFAOYSA-N 0.000 description 1
- VRXIOAYUQIITBU-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCO)CC1 VRXIOAYUQIITBU-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 1
- HKQOYPTZCIPZBX-UHFFFAOYSA-N tert-butyl 4-[(4-aminoindazol-1-yl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C2=CC=CC(N)=C2C=N1 HKQOYPTZCIPZBX-UHFFFAOYSA-N 0.000 description 1
- YNJSMLGKVOCZRG-UHFFFAOYSA-N tert-butyl 5-(bromomethyl)benzimidazole-1-carboxylate Chemical compound BrCC1=CC=C2N(C(=O)OC(C)(C)C)C=NC2=C1 YNJSMLGKVOCZRG-UHFFFAOYSA-N 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WARKYKQCOXTIAO-UHFFFAOYSA-N tributyl(2-ethoxyethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C/OCC WARKYKQCOXTIAO-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 201000001105 ureteropelvic junction obstruction Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DSDCDMKASWVZHI-UHFFFAOYSA-M zinc;2-methanidylpropane;bromide Chemical compound Br[Zn+].CC(C)[CH2-] DSDCDMKASWVZHI-UHFFFAOYSA-M 0.000 description 1
- GTJUPSNUGOBNMF-UHFFFAOYSA-M zinc;cyclopentane;bromide Chemical compound Br[Zn+].C1CC[CH-]C1 GTJUPSNUGOBNMF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (11)
- Szabadalmi igénypontok i< Egy l'-es általános szerkezeti képlete vegyület X ° )=( ^ / Rí~”\ /"N\ ^--X ££': o í\^ V vagy ennek egy gyogyaszallJag elfogadható sója, ahol: R t jelentése; hetArlcüHgjm", hetA$ÇM&v. h^t&rSçHa- (3~ §0 olkloâikll}"CH2'·: fietOki^CHg-, ArtfCH^jrr vagy (N~1~ 30 sitii )p I nd I non! h CH g-: hetAr'l jelentése egy 6 tagé heleroaril, amelynek gyűrűjében van 1-2 N-atom, és adott esőiben egy vagy több szubszhiuenssel szyhsztltyált egymástól függetlenül választva az alábbiakból: {IfoCjaM, f1-4€)alkoxis halogén, GFg vagy (SfoCfotkloalklt; •m jelentése Ö, 1 vagy 2; hetAi‘2 jelentése egy 5 tagú heiaroani gyűrű 2-3 gyűrű-beteroatommal, egymástól függetlenül választva N és $ közöl, ahol a nevezett heieroatomok legalább egyike N, ahol az említett gyűrű adott esetben egy vagy több szabsztituenssel szobsztltnáti egymástól függetlenül választva (1 foCjalkl;-csoportok közül; 11 E?BQ~ 1 61444 MOl FP 2 951 939 81 hetAr^ jelentése egy blelklusos 5,S4uzk>náit heteroarl gyűrő, két N-etoemnaf a gyűrűben; heteik^· jelentése egy 6 tagú telített heterociklusos gyűrű 1~2 gyürü-lietematomi^al egymástól függetlenül választva N és Ö közül, és adott esetben szubsztlfuált -C(-0)(M6C alkll) vagy -0(0)0(1 »60 at kit} csoporttal; Ap jelentése fenil, adott esetben egy vagy több szubsztltüenssel szuhszllfuálva egymástól függetlenül választva a következek közül: halogén, C1~6C)alkll, CM, CFg, OH, (MüCtalkOKl, ~(C -0}0H, ~C(0)0(1«6€ alkll)í: »C(~0)NRaRk vagy benzüoxi; Ra és R& jelentése egymástól függetlenül H vagy (M eC)alkli; ; n jelentése ö,: 1 vagy 2; Rtí jelentése H, F. Cl vagy CHg; Ró jelentése H, F vagy Cl; R4 jelentése H, CN, F, Cl, Br, -ÖMe, -OCF3, »CF3, ~CH(0H)CH2ÖH vagy »Cí^OjNHi; Rh jelentése a kővetkezők közül választott: H, halogén, CN, OH, ..................... hét Am,............................................................... .................... hét Ar A heteiké, heteikig 1 “4C~alkil)»s lietCIkHt 1 »4C)alköx|, he tClk|S(1 ~4C )a I ke xl, (1~3€ aikoxäX 1 >4C)aikoxi h$droxl{M1C()alksm., d!füdrOxif2~6C)s!koxk (1“60}aÍkoxk {foldroxíf 2-40 }a íikit lem ! ne j~( 1-40 ) alk! h |f 1 ~4C alkokéi --4C a:!ki!)arntnol(1 -dCjalkltJdtCI -40 alklli}amiiaol(1 ~ 4C)aíki, (1-4C aíkil)0(~OK hkiroxlll "6C)alki:k did Id roxl(2" 60 )a I kils íd í( 1 -SC a Ikl jamlnojí 1-4C)a Ikexh N~( 1 -30 atkljplddlnon, ...........................neiAAk................................................................................................................................................ def Clkl^CI-OK (hetClk^)~0"S beiC!kl% 1 ~40>álkgki, dpuof“ámiao(1 -4C)alkoxi, [|1-4C álteí)karböailamldpiuöf| 1 ^Cjalkoxí; (1 -40 al kI }C( ~0 }N· H ( 2- 40 jé! kt !4!ξ>, ( 1 -4Cal kll)ÖC( -· ö )-, v a g y RCR^NC(“Ö}-; hetAr^ jelentése egy 5 tagé beteroaé! gyűrű 1-3 gyűrű-heteroaíommai, egymástól függetlenül választva N; O és S közük ahol az említett gyűrű adod esetben egy vagy több szu bsztit uensset szubsztltuált egymástőt függetlené! választva (l-üC)atfdf és P(1-3C afktÜaminojCHg- közül:; hetém jelentése egy 6 tagú heteroaril gyűrű 1-2 N heteroaiornmai a gyűrűben, és adod: esetben egy vagy több szubsziituenssei szubsztltuálva van egymástól függetlenül választva: f1-60 iatkll-csopnrtok közük hetAdl jelentése egy 8 tagú, részlegesen telítetlen, bldklesos, heterociklusos gyűrű 3 N-atomma! a gyűrűben, és adott esetben egy vagy több szubsztltuenssei szubsztituálva ven egymástól függetlenül választva (1-6C>alkil~Gsoportok közöl; heteiké jelentése egy S~7 tagé, telített vagy részlegesen telítetlen, heterociklusos győri 1-2 gyikű-hetematornmal N és Ő közéi választva; ahol az említett gyűri adott esetben egy vagy több szubsztltuenssei szubsztltuáit egymástól függetlenül választva a kövitkezök közül: (1-öQalklL Ndroxi'(1^6C)alkll, OH és oxo, feltéve, hogy az említett oxo-csoport egy szénatomon helyezkedik el; heteiké jelentése egy 4-6 tagé heterociklusos gyűrű 1-2 N-atommal a gyűrűben, és adott esetben agy vagy több szubszhtuenssei szubsztituálva vna egymástól függetlenül választva akővetkezők kozö' *ÖO;W. 0 **CVjlkoxi és halogén; heteiké jelentése egy 4-7 tagú heterocsklus 1-2 gyűrű-hetomatommal, egymástól függetlenül választva N:, Ô és S közül, ahol az emlfeil győriben lévő nitrogénatomok közül az egyik adott esetben ÍM|Ö)~öá van oxidálva, és ahol az említett,, gyűrűben lévő 8 atom adott esetben SO vagy Sör da van oxidálva, és ahol: a hetCiktó adói: esetben jegy vagy ; több szubsztltuenssei szuösztítuált egymástól ; függetlenül :: választva a következők közül: halogén, ÖN,. {1-6€}aikil, (1-4C aikoxiM1-öC)alkil, (1-4C)alkií-OCteö}- és (1-6C)a!koxi; betCIkl^ jelentése egy spíro-beteroclkius 2 gyűrű-heleroatómmal egymástól függetlenül választva N és ö közül," ahol a hetCíktó adott esetben egy szubsztltuenssei szubsztituálva van (1-6C)alkll-csoportok közül választva; heteiké jelentése egy 6 tagú heterociklusos gyűrű 1-2 N-atommaí a gyűrűben, és adott esetben egy vagy több szubsztltuenssei szubsztituálva van egymástól függetlenül választva (1 -ÖCjalkíl-csoportok közül; heteiké jelentése egÿ 4'6 lágy h0t@rocilc!ysos gyűrű j vagy 2 N atommal a győriben, és adott esetben egy vagy több ezubsztituenssol szybszibjalva van egymástól függetlenül |1^QatkÍ és OH közút: :: hetOtkP jelentése égy átbidelt, § tagé heterociklusos gyűri 2 győrü-i^emétömmét lioiMsrileti..... y hateroatornDk közül legalább az:egy& M és aboi mjmMm i: gyűri ^ adott :::: esetben f|”60)aiktbcsoporttal van ;:;;; is2.y'bsztl%ïélva;: Rc jelentése H vagy í1-4C)aÍkk; :Bá; jélèrÂe^t^Olatkii HêtCikl'10-, anilno(1--4C)alklvegy ; :jpf1«40 atii|amtfíóÍi«4C| mg heteik! * 0 jelentése egy 6 tagú bétereoiktys egy «ογ?Μ a gyűrűben és adott esetben egy vagy több szubsziituensset szubszltualva mn egymástól függetlenül választva (1~ !! 6C)a!kikesop»k közit;: és Rb jelentése H vagy 01 & Az 1.. Igénypont szerinti vágyóiét, átallt* jelentése hefAr^CBgy*-hetAÄHg- vagy hetAÄH^ 3« M1-2. Igénypontok bármelyike szerinti vegyülei ahol R * jelentőse hetÁr^CH2)m'"-
- 4, Az 1-3. igénypontok bármelyike szerint! vegyüiet, ahol ni jelentése 1
- 5, Az 1. igénypont szerinti vegyüiet, ahol R* jelentése (3-60 cikloalKÍlj-CHg** heteik! 1CH2n Ar1{CH2)rr vagy (M1-3C aikiijplridlnonll· CH2~-
- 8, Az 1-5. igénypontok bármelyike szerint! vegyüiet ahol f$: a következők közül választott: H, halogén, CN, OH, hôlAr*, hetAfS, hetCiki2, hBiCikß(i~4G&M)~f heteikig 1 ~4C)a!koxL tietCiklS(l~4C)aikoxi, :(1--30 afköxQ(1-4C)afkoxk hidrokltl-bCjaikoxh d'ihi.droxi{2“6C)aIkoxi;i (1» 6C}alko-xi, pid:roxii(2~4ü)a'ikil)a.rnIîioH 1 {(1-4G afküXiK1~4C alkl;l}âmlno](G4C)alkks p{1-4C a!kii)am]no]{1-4G}al:kils |1~4C bidroxlj 1 ~6€)&ikii, dibidroxip-dQaiki!, p(1-3C a!:kil}amlno)C1'~4C}alteí és NK1“3C aikilpddinon.7, Az 1-6. igénypontok bármelyike szerinti vegyüiet, ahol R3 jelentése hetülkl4(1~4C)aÍkoxl vagy heteikig 1 ~4C)alkoxl S. A 7, Igénypert szerinti vegyüiet ahol jelantésa heteiktől -4C)af koxk 0v Az 1-8. Igénypontok bármelyike szerinti vegyülni ahol R2 jelentése H,
- 10. Az. 1-8. igénypontok bármelyike szerinti vegyüiet ahoi R* jelentése F vagy Ci
- 11. Az 1 ~δ. Igénypontok bármelyike szerinti vegyüiet, ahol R2 jelentése CHg.
- 12. Az 1-11.. Igénypontok harmelylke szerinti vegyüiet, ahol R3 jelentése B,
- 13.. Az 1-11. igénypontok bármelyike szerinti vegyüiet» ahol R3 jelentése F vagy Cl. 14» Az 1 -13, igénypontok bármelyike szerinti vegyüiet, ahol R* jelentése H.
- 15, Az 1-14. Igénypontok bármelyike szerinti vegyüiet ahol R6 jelentése H.
- 18. .Az 1. igénypont szerinti vegyüiet a következük közül választva: N-(l4:(6~|zoptopll-plhbin-241)metll)-'3-metil-1H~lnda20h4-li:p?~ (2"ntorföiirvetoxl)Í!prdaz.o[1 J-ajpInöln-S-karboxamld; T"(2-(4»etílp!pemzln~1''!l}e!oxi|'-N~(1-((6'-izopropll~p1rídm"2'' i!)melH^3~meti^1H~ilπ<lazol·4-|)imi.cîa20i1 >:2rajpifJdirK$~ karboxamid; ?-'(2~(2í6~dla2asplrop.3]h0ptán~2-4:l}eloxi}'-^~|1'-C(6~lzopmpíí~ plryin-'2d^)metyV3~rn:etíl~1H'^dazol'4~y)im:|:dazí>[1 ,2~ajpridin~3-karboxamid; :N''(1''((6a2ôpr0;pii:"pi;ndir>'44i)metii}~3~rriatil~1 H4ndazoM-il>~7-· (S-Cö'-matii'^^'^lazaapiropJlheptán-^a^etoxdimkJazoltJ·-a]pí ndin-S'-karboxam id ; 742~(2~oxa-4'-azaspiro|3,3|hep!àn-4"i!)aloxp~:N-'(i-'i\e~ i2opröpB--pindín-4-21}niediV3~metik1 H'-indazöl'-d'-ijímidazoll ,£-aj pirid in-3- ka rbox am id ; ?-(2"(4-i2O:prdpíl~'pi'pára2Í0-1-i)@töx^-l1-C1>(Ce4zopmp8plndia- 2a!)PielÍi)47Miietli-1HdrKlazoi“4-ii}imidazí)[1,2--a]pirsdsn-3-· karboxamid; N~(1-((6-izopropii''PÍndín~2di)nietii)--3-rnetib1 H4ndazol-4~iÍ)~7- (2-({3S,5R}"3;4î54nmeÜ!“pâperazio-1âl}etox!}imidazon,2- a]piPdin-'3'':karboxa?^ik1; N~( 1 ~{( 1 azopropit-5-nietii -1 H-p$razoí -321 }metii)”3-metiM H-:indazoÍ“44l)*T>{2»(6-'melil-256'diaza*apiro[3.3]hepíán~2~ ii)eioxl)imidazöf152~ajpirïdiP-3"karboxamld: N-( 1 4(1 dzópropií-S-mepM H~pirazoi<4ii)aietil)“3~rnati:i“1 Ha indazol~4di}-7~(2-((3S,5R)-3s4,6-trkaetH- piparaziml-iiMoxl)lmidazo|i ,2~a|piridin»3Hkafboxamid; N~( 1 -((1 dzopropibS-rnetlM H-pirazoi~3~il)«'í:afii}-3~meil~1H-indazok4"ii}-7“(2-(4-izöpmpii-'pip6fazi:n~1-'il}etoxdimidazo[1,2~ a}piodln"3''karboxamid ; N414(1 dzopropii-5-matsim H~pirazPl-3dI|melil}"3~melil'-1 H~ indazoi-4ai)-'7-'(2-'(4-'medl''1 ,4~diazepáiv1 ~ii)atoxi}imldazö[1,2-a}piddin~3~karboxamid; N-(1-({2-!zoρropi!"bazo:l·4-i!)madlr3-m:ati1:~1Hdndazok4''II)-7'' (244a0pti!-piperazi:n-1-ií}ptox:í}irpidaza|1,:2:''a!pindín:''3- karboxamid; (2~í6~meUí*2}6-diazaspiro(3/3jheptán"2'-ií)etoxi}imiclazo('1,2- a|p«di^3~kaiffeoxamld ; 7-(2-{2:~oxa-8~azasp'rö|3.3|Nepfán-6~íí)eto'Ki)~'N>{1~f{2“lzopropil· íi:azo!'4~íBm:0!i)“3~rnetll~1H'%íd3zo!'4'-r!)ímídazö[1s2-'a]pjnd:sn--3·» karboxamid; T*C2~C4~feopropf~pipemzi^14l!)aíoxí)“N“{ 1 ~{{2-izopmplNiazol«4'· äl)matind4nietÜ4Hdndazöl"4~H}s?Tadazo[1,2~a]pindin~3~ karboxamid; N4J.4'(e'“dk!opmpil:^ryib~2-4í}me.t!|:)~3-met4~1H“mdazü)-4~i'l)“t* (2^4420propihpípera:Zla>1~l)8toxi]iímidazó|1s2~á|pridM~' karfeoxamkl; 14(ö<^löprop^plHdi?i-2Hl}di8t!l V3-metk4 HHndazok44i}-7“ (2~(4~aîîlpïpp:razb-14!)atpxi)imiéazô[1s2>ajplfi<lln!ll”3~ karböxamid; M~( 1 -(i6“€iklppropi~plftósP~24í)me't'i!}^-metl{~Í H4ndàzôï~4-»l)~7·* (2aTior!ölln-etöx!)lmlí!axo{1(2m]|)ld<lm~3~kafPoxam!cl; N"{HP:~clklopropíP|^ridln«24l)malií}~3~metil~TH4nd'azol*44!)-7» (2~(3>3;4-lrlmoliPplpera:Zln"14l}etoxl)irnldaz0|l;2~a]pdldm-'3'' karboxamkf;; :Ν~{13(:β4^ΙορΓ0ρΐΙ~ρΙίΙ3;ΙΠ"2:3Ι)οιβΐ!|)'~3"ΠΐβΙΙΙ4Η3π^ζόΡ44Ι}-'?” (2-(4-(2-•xaelDxke!liplperc5zla“14l}etöxl}|mldazo|12"ajplrldm:-3·-karboxamld; M-(3-kfór~1 “((8mlkloproplPprddíb~2~k)motl! )* í H"<ndazo1~4~iÍ}~?~ (244‘dzöpropii~piperazln-1dl)etoxlkmldazó[1<2'-ál;plrídln''3'' karböxamid; N<14(6miklapropll''plrldla-2''íl)raetd)~3"duor'lHdn:dazok4dl}-'7- (244~lzopmpk'#perazln-4dl}etox;}lrYdd3zo[1!2'-a|pkldrb-'3'· karboxamid; (SI-PI'kS^lór^die-clkldpropiPpkldln-^dOmotkVIH'-Indazöl-^- ii^?42K^»4“dimeti~plparazin-1di)etO:xi)i:midazo|1>2^ajptn<lln^3^ karböxamid; {S)''N''('!'<(6~dkiopröpäf"piri:d!n-2-4^melil)~3-'f!uor-'1H--i;nd:azö!'4~ il}~7"{2~{3,4"di:m'etíi“piperaziri” 1 dbetoxplmidazoft ;:2--aJpindiri--3·'· karboxamid; (S 1 Hl)-eto-?€i}-M-C1 "<(0-is:opropii- piád ia- 2 - il Imeill V3 ~ m e til ~ 1 H~i ad azo i ~4 4 l:)l rn kl azo [1,2~a]pí ri:d Irv 3"karboxamk1; (S>N'~{1^{e:-«íklópropíkpírídfn-2*8)matil)*3»meil»1H4n:d!azöÍ~4" ií)~7“r2H:3>4-d!meíil^iperazin-14l}eíoxi)!midazoí1,2>a]piridin>3- karboxamid; |R)~iN~t1~((eK3klapropil'-pridm--230nietlî)~3-metsk1H-3nda2o!-'4~ if}'-7~(2~C3s4~da^ety:“plp@ra25n--1 4i)etoxi)imidazo|1^2^a]piddin~3-karboxamid; CR)'T-(2-(3î4-dlm:eÎÎ!>'pÎpera^n''1 <<8^s:oprapi!" pirid:i;n:~2-Hi)metii}-3^nietik1 Hóndazobdailiniidazofl ,2>afplndirv 3~karboxarmd; (S}'742~(3;4--dlrneiH:~p?perazia''1 ~l!)eioxí)~N~{1 ~({ί ~izopropii~§~ metiP1H--plrBzok3''rl)ry5gtsl)-3"^e!k"1H3ndazöP4a^)iniic!axo|1s2-· ajpiridi n~3Hkarfeôxamîd ; '(SH”|2~f3,4-dlme^l-piperazin“1:-ii}atox:0“N*Ç1"{C2Hzopropil·'· |iazo!“4"ii)metil)*3-metil-'1H~indazoi''4''íl)ímídatol1>2~alpiridlP"3" karboxanmd; {S}'-Np1d{6deycd)ui^pkídin"2d!)aietH)"3':niet:y~1Hdn:dazoP4dlP Tp^a-'CS^Kiimetk-pùoaraxhi-IdpetoxpHiikiazo^dk'-alpindlndk karboxamid; (S^N~(1^(6-oklobutH^iddi:rv2-il}me!;il>3“iiiiatli~1H4ûd:a2oM~lf}- ?d2d3;4''ddTsatiPplperaz|n-Rdpatoxl}irnkaxo!1;2”alplädln~3“ karboxarrud; (S}"IMd1ii6<iklopant2pPidm-2-al}meyi}"3"P>el!l~1H-'lndazoP4'' 4)“74243,4~dimety~plpgrazin~1-il)atöxl)lmldazö[1 s2mip!bdin-'3~ karboxamid; {S}-'?"(2“(3;s4»dim.etiil“piperazm~1 ~l!)etoxi}-bH1 pidd]n:»24)malil)^3-mödM/H4adazök4~il)imidazöi1· ,2«a|p«dirs~ 3~kad>o.xapki; (S)^'(2--{3{4-dimelH~p?perazúv1~il}etoxB~N~(3~meli!~1~((6~metí!-pirid ín "2 41 }met!l}-1H -i nd szol -441 )? mid a zo [1,2- a)pi bd i rí- 3 ~ karfeoxamid; (Si'-TdSdS^-dimatii-piperazin'd-ddetoxd'-lddl-HCS-eti-pIdclin^'' íi}metii)~3-metil“1H“indazöf'“4>íl)imídazoi1 s2sa]pífídln-3~ ka.íiioxarmd; M-{ 14X(>s2Bk'“buíilrpírídin~2-ii)rn:etH>3~metíl-1 H~sn<lazoi~4~il>?~ (2:4CS>3;4aiimetíi-'psperazin"1 -fi)etoxi)imklazo[1 ,2-a]pi.ridin-3~ ksrböxamkl; ( S )-7-(2 -( 3,4-dim éti í ~ p\ peraxi n-1 ~i:l)etox i)~N-{3-metil *1 ···( (5 -propy-pridin~2dl)rn6ti!)-1 H-i:ndázol»4-íl)imídazo[Í ,2~a}pW\d\n~%~ karboxamid; (3)-7-(2^3., 4-dlmetikpiperazin^i4l)etO'Xí)^N^i4:CS4zDpropíi~ pindindbai)aietii)d7-metii-1Hdndazói-4-!|)iniidazo[1 ,2-á]pirí<IÍn-3~:kaTbo.xamid; (S)-7-(2-(3;4-dimetii-piperazin“idi)etoxi)-Nd1-((6dzobutik pd!di:n:-2-il)meti!)~3"Pietii-1H-indazcd~44i)imidazö|152-a!plndin>· d-karboxamib; (S>7-(2“{3>.4~d^etiÍ*piperazini‘1-il)etoxi)“N“(f“C('5“tiüor~6<· szopmpil“plddin-2"i!)mebl>3~meti1-1Hdndazol'4'-li)lmldazo[1,2-a] pír id Î n-3- karboxamid ; (8)-7-( 2-(3;4~bimdtikpiperaxin-í -ií)eloxi)-N~(3~metl-1 -(2-(6-meiii-piddin-2dl)8:bi)'>1H-indazDi-4-ii)lmidazo(1<2-a]pindin-3“ karboxamid: (S)-N-(1-{(p-ciki(>propii-pindm-2~ii)metii)~5-f|yor-3-rnetii~1H-indazoi-4-41)-7-(2-(34-dirnetii-piperazin~1~ií)6tóXi)imldazo[1:2~ ajpirldinift- 3-ka rboxapi id ; 7-(2-(4dzapropli~pipaTazin-1:~il)atóxi)-N~(3~metil~í~((5~(tnfiuor-pietii}pindln-2-ii)pietil)-1 H-indazoi-4-li)Ípiidaza{1 ,2-ajplndin~3~ kadxsxaaiid; 7«<2-(4-ízopropií“píperazín-Í“ii)etoxi|-N-(3-m@tf:M-{(6-(trifluor» metii)piddsn-2-ii)métii)-1Hdndazôi-4-il)imidazo|1i2-a|pînd:in~3- karboxamid; (SVN-( 1 “{{ö^zopropil-pirrdlri.^jO^etil^S-metil-l HandzzoMal}-?~(2~{3~metít~pipefa:zi.n~1 ~ií)etoxi ,2-ajpMfh3~ karboxamkl; N41-<(6»clkioproplbplrlc!ln~2"IOni®tk}~3~met?b1H'4ndazöb4dl)''·?·« {2'”{4-metihpíperazM~íl}etoxí)ímídá2o[1 ,&a]pirtdiri-3» karhoxarnid; N"( 1 »({'1 -izoprop'íli-1 H~pirazol-34l)metii}-3«metil!~1 H-índazo!^- i:í)“?~f2“|4“metii“Píperazí?i-1~i!)etoki)im.ídazö[1<2-aJpirid(n-3- karböxarnki: M»( 1 »((1 -izópropIM H-plrazoi^it)metH)^me!iM HnndazoM- ii)~T^2“(4^zopropií«piperaz^ 1 4l)etox:í}imidaz0f 1,2-alpi?idü>3-karboxamki; MdSooetlM ~((6"metl''pírlciln”2-Pb^^ll)"1 HándazoR-ll>7 -(6-metb"p^din~3~k)irnidazo|1>2~a!pirtóm'-3'4aTboxamki; N'-CSaneilbl i -píri d ín ~2-I I ti I )-1 ·Η4ηάβ2θΜ41:}-?~ (í ,2,3 J4etrabidro^>kk!ln''4H0k?adazo|l J~a]pírídirv3~ karboxamki; N-R-meliM •({6a?iet!!--pndln"2dl)rrietl!}-dHdndazok440"?'· (p!pericka:~44l}kai:kiazo|14^'8]pk1din<bkarboxamid; T-fluor-'N-íS-mePbl ~((6~Piôtiip)lryin<'24brnet!f}-lHdndazob4» iOimida^oli^-alpiddin-S'-ksrfeoxamid; N~<3-metíI-1"«e~m-eiíí:~plríiái=n~2~íí)metil)-1 H-indazoM-llh?·' (pkroüdin~1~k)laddazö[1;2~a!pndin'-3“karfeoxamld; N-CB-metlbl “|(ö-matii:*piridin-2”ll)metl'l)>1 H~!adazPb4-4b~7~(2~ (pírra íi dl n ~ 14 l}atoxi)l rnldszo 11:2 ~a] p ifi d m -3~ k a r boxa· m id ; íeixabullí 442~(3~(3~met0~1 ~( ( 6~ metH~p I ri d I n - 2 -> ii ) m éli )~1 H-lndazoM4i~karbamoif)imida2o£1,2-a]piddirv7-ii~ oxi)etil }pl per az I n-1 ~ ka rbo xi lát:; ?~(2~hldfOXÍ-etoxi)~M43->nietk"1 -((6"metíl~pindiri~2~ii}metil)~1 H~ indazol>44;i)imidazof1s2"aipiri£iir>3~karboxamid·; 7~(2>3-dihidmxi“propoxi>N~P~^^''1~((8~metii-'pindm~2“ ifymetMM H^ndaioMHi }imidazo|1,2-a|pifidin-3“k:8f box-amld ; Nap^m0tíl-1~((43aiiatlkp^írklki-2dl}aTetk}~1H-índazol-4~íi}-7“(2'· mo ff öli a-atoxi }bíi ki azo [112'^]pl nd i n 4k'-ka rboxa add : 7~(2'-ídlm:e:!l^-a:mmo)eloxl:}"N:-'i3-meüi"1"((6''meO!''pkidlív2-H-iiielazo:M-il:)i:mid;azo[1 t2^aJptndin~34:arboxsrrùd ; i}*mîëazô{152-a!piri<lii>3-k.arî)oxamid;. 8-cian:O-N43~m:e!l'-1d(e''ai0!bpsndsri''2dl)medd'-1Hdnbaz0b4~ ít)imid azof 1,, S-alpInd m-3~kartox a rn id ; 74\i:drO:xdNd3aii:eti-1''(|8~metldplndirv2''idni:etld“1Hdndazod4·' iprnid azof 1 2-alp Mûm-d* ka rboxam is! ; N43aBedI''14|6~meti~ppd4^2d!}nietkl~dH'-mdazol»44l}~7--C2:·' ( pi parazi a~;1 ~i! }etoxl )imida zo{ 1,2 -a] pi ndi rv3-kar boxa m id ; N ~(3~metil· ;i -( (6-m étül-pirkiim-2 :- B~i ndazo I-44Í )~7~( 1 ~ aietil'€^xc>'4í6^xlilddrö'-pl:ddkvS~i!)iíaidazo|1;2''a|pindin~3'' karboxamld; N:d1d(8azopmpidpiddia''24ii)mati0"3-rnetii-'1Hd:ndazol--44i}--7·· {2-<4*metii~piperazi!Vl4l)ef0xi)im;ida.zo|1.ÿ2"aÎpiri^ln~3-ka rboxam id: N41<(1dz0p:mpil''5"metlk1 H"pirazo1~3d!}mety>'3~medl~1 Η» iodazoi'4--il)'4-{2'44zaal4-pi:pamzin-dd!}etoxi}i:midazoi1s2'' a|piridin-3-karbaxarTdd::; N-(3-metib:14(o-faatiPpirldiO''2-yi)metil)'dH-yndazoi'4dl)-74l'' mail!-1 H~p|rázo!-4~i }i ra k!azo| 1,2-a'jpiπ din~3~ karhoxa rn id ; Η-ρΐΓ^ζοΙ»44ί)-Ν-|3··π^6^!~1~{(ί6“«ιβ;|Ιί~ρ!ΓίίΙί;π~2> il )metsi)~ 1 Hi- indazol~4~:ll)kaldázó[ 1,2-a]pi ridin~3~karboxamid; NK3kmètsl4HX6~^ Hdndazbkddii-Bdl H- pirBZôi>44l)ind:dazo|1,2-alpiddin'-3'-karpoxamld; N:'-(3~a^eil'd:-((8-'matil~pirl(lki4'dl)matif)-lH4ndazöl4dl)>'7''(1'' aietil-l H"plrazol~5~ií)imldazo|l î2'-alplridinilk3-'k:ârboxamid; 7~{2~idkaablmmi:πo)at!l}~l4~{3~Pletl^1~(c8“a1e!íl·plπdin-2” il}me!il}~1H4ad'azoM41|im:idazb{1,2~a|piridin-3"Narboxamid; 7^2~hldroxi~elíiHN~i3^etll-4'4;{8“meti1»pirkiiin“24í)meti'í>ÍMk lodazo M-il }imiû azo |1 2:~ a|pl rid i a -34a rboxa m id ; ?-(242“metox;l-effamim)ei1|-'N-(3-m@ti!-l4X6-metii>piddfb“2-ll|aiekl)~1 HH.ndazoM4l)imi:dazo|1 ^-alpindin-'B-karbôxamid; T ' < 1 ' ( :2 - h kl rox ï -îs t ? la m ? n o} e tB ) - N " ( 3" rti e 1:1 ξ"" 1 - ( ( β- m e t î ί- ρ I ?1d ί n " 2 -ilimetyj-IH'indazol^'iliLmloazollS'-alptrki^vS-karboxamkl; ?“( 1- Nroxi-àtil )-N~(3-metiM' -( ( 6 - m etil "P î ri d m - 2~ il ) m til )-1 H -mds2soM~íl!}imíd:azo{i ,.2-a Jplrldin-3~karboxami:d ; N'{3aaetk;''lH(e"^^>"pddín'-2-kÜmetl}~1H-in<lazo!~4ai}~7~(2~ (pír rolidirM 4l)etii}i:roid szo[1 ,2-a Jpindih-3-ka:rboxamíd ; (4~m«®~piper8zln:''1''ilf)etl!}1mldazof1.2-.8jpindin-3-karb0xa.mld; T-acefil-N-CS-mefii-l-Cie-metii-pindin^HOm-elil^l HdndazoM- il }imidazo[1 ,2~alpindi{v3-karboxamid N-C1 -banzif H-indazol~4-‘il;>-7-|2“.rnetoKi- 8toxí>ímidazö|1.2-a]piridi:fiiil~3-karl3Dxamid:; N~C3~metil-1 -|(6-mBtil»pi:rid:in-*3-ii)môtiiH H-indazoi-4-si)saddazo[t;2>a|piridindî~3~karboxaadd; 7-(2-metoK:í-etoxiJ'-H-(3-metí'M-({tetrafiidm-2H~pifán-2-il).metil:}-1 H-indazo!-4-ll>lniidazo|1 s2-a]piddin-3-karboxamld; ?-(2-m8toxf.-etoxi)-N-(3-metli-1^leîrâh'idro-2:H-piirâiin~4“ ilJmetiiJ-IH-indazol-^ilJimidázoll.S-alpindin-S-ksrboxámid; N-{1-{cäklopropii»m6til)-3-i'netil-1H4ndazol~4-ii}-?-(2-m0töxi-' etoxi}imidazo[1 >2-â]pifidiniii-3-kafbôxamid; .N-{3~metll-:1-((6-metii-pindin-34i)meti!)-1 H-.ind8zol-44l}»7-42-.{4~ matt-pipa rázin-1 - il}e toxi )i ni idazof 1,2-a]pi ddín-3-karboxaadd : Id-(1 -((6-etexl-plndln-2-il)m0tll)-3-'metil~1H"lndazoi"4-ll}-7-(2~(4- metlPpiperazIrvi-llielMipnildâZDlI^-alpIrldin-S-karboxamld; N-(1-(:(6-m.etoxi-piridin~2-íl)metii)-3-m€ti:l-1H-indazoif~4-ii)^{2- (4~metil~plperazln-1:-ll}etoxl}lmldazo|1;2~a}piridln~3~ karboxaadd; Ν.-{3-?^0ΪΐΙ~:1-{{2:-Γη.8!ϋ-Ιΐ8ΖθΙ-4«ϋ)ΓΤ\β1ϋ}-1Η·-ίβ08ΖθΙ-4-ίΙ}-742-{4-· mptil-psperazin-1 -il)etioxl)lmidazof 1 t2~aJplndiri-3-karboxaadd; N-(3-metíM -((6"metil-plrιdlπ-2dl)metli)-1H:dmlazol·44l}-?-(2-(4-metil-'pipefazin“1-ií)atoxí:)imldazo|1{.2-aJpiridin-3-karb'Oxamid; N:-(1 -danzi-1 H-lndazDl~4-l!|-?-(2-morfolia~@toxl)lrnidazo|1 ;2-8|plndlnllb3-'karbox:amidl; N-(1 -benziM HdndazoM'dK7-(2 ,3-díhídro^i . propoxi)imidazop:2-a]pind)ni^i~karboxaml^ N~(1-benziM HdndazoM4l)-7ïhjârôxMmidazoll.2-ajpîddin-3- ; karboxamid; Mety-3'({4~<7-'(2-'metoKHetoxî)srnidazo[1 ka fboxamidoH H 4ndazoM *il)metM)benzoàt; N4143-karbamoil~benzil)-1 H-inda2oM>i!)>?>{2-mefoxh etoxi)i^idazo|1,2~ajpindini!-3~karbQxamid; 7-(2-Meioxi>et<3Xi}-N"(1-{3“<metil~kart}amoil)benzH)~1 H-indazol· 4-ji)imidazo(1,2-a|piridin-34wrboxamid ; Metii 3-{{4-(7'{2''(4'm€ft^pipara2in*l4l)eioxi)imidazo[i ,2* a]psndin-3~karboxamido)4 H-indazoî-i -ii)me-tii)benzoàt. N-( 1 H343jimaiMarbamoi0banzH)~1 H«indaxoM“ii)«-T“{2“<4~ maitl-piparazin^dOetoxOimidazoCi^-alpindin-S-karboxarimd: 7-(234“Hietii'piperazin~1"H}etoxi}'-N“(1-(3"(tnf:!uGr'metll}benzH)-' 1H-indaxol"4-il)!midazof1 ,2~3|pifkk?v3~ karboxamid; N4J43-danobenzH}-lH4nd8ZQM4l}-7~{2~(44raeW-piper8Zin-1~ n)etoxs}^^idazoi1:2~ajpiridin-3~karboxamid; N-(5-ktör~l 43-(tdfîuor-œetji}benzilr1 H4rwiazol*4«H)-7-(2-(4- metH"piperazsrj'-1 4i)at<3xi)irnidazo[i ^-alpinpin-S-karboxamid; \ v s*\ky > X 2" 'Γϊ ' Ή-«'\ί_\ 4« ^7-(2-(4- meti!~piperazin>1'il}etoxi)imida2o[i ,2^]pirWin-3-karboxamid; 7-C2-{4-m6tiÈ-p»peraziiv1 âi)pîoxi}"N~{1 •·<ρίΗΡ?π«3«Ι}~Γ?ιβϋ!Η Η-indazoP4-i})irnidazo(1 ,2-aJpiridin-3-karboxarnkJ: 7^2^4-M*tMperaz«n-1 ~i\)eioxyU~i 1 -((5*{tnlluoMnelil)piridfo- 2~il)matiiM H~inclazoi-4“H)imidazol1 ,2-ajpindin~3-karboxamid; Ν41”{(1-π^6ίΗ*2-οχ·θ"1 s2-dihidfO-piridîn-3“il)maUl)«1H"indazol· 4>i})-'7~{2~(4~meitl-piperazm-1-íl}etoxi)i^idazo(1>2>a}pindm>3-karPoxamki; piperazin-1-ii)6fioxi)imiclazo|t,2“a]piddin~3'»karboxam<d; N~( 1 ~((1-metäl'-i H-4midazol~44l)metH}''1 H-indazoi“4-il)-7*(2*{4“ pietiPplperazlP^1>il)efoxj}imidazon :2-ajpindin~3~kafboxarrkd;. ?·-{2~{4~^0|ΙΙ~ρ?ρβ·ΓβζΙΜ>ίί^οχΙ}-:Ν~(1~(2:φΐΗ^^-24Ι)©!8ΗΗ- irídaz0'M4l)imí<la:Z0{1s2"a|pí:r1dlní!“3"ksrbDxamld; N"íl "í(l H»lse.nzo[dJimidazo!i>5~H)métifH Ηa^:oi^)-7-(2-(4-irieil-pIpemzio-l^l^loxilimidazofl^-aJpiddift-S-kafboxamld; Ν:~{1 ~( 2:< 4~d iiyo r-foen zi I}-1H - i nd azó V4~y )-7-(2-métoxi-etoxí)Ímidázol 1 ,2-aJpmd! n -3 -karboxamid ; H41 -(clktopropil-medlj'-l HdmiazoMdf )-?-( 2~metoxf~ elöxlImldazoll^-alpindin-S-karboxamid; 7^2~^0^^-δ^όχί)-Ν“(1.“{ρΐΐ1ζΐ!Π~4“ΙΙ~^βΙΙί>1·Η4η<ΐ320ΐ-4~ ?!)imidazöf1 v2-a]piddin-3-karboxamid; 7-(2-meloxl~etöxO;^'(7-(pridá>2-l-aiati!)-1Hd:nd:azob4- apmidazo|1,2-aJpiddía“3“k3rboxaadd; 7^2^Θ!οχΙ~βίοχΐ^Ν'-(1'-(Ρβ^ΡΙΡ:Γθ~2Η^ρί'ΓΒ^4Ι|^0ίΙ)~1'Η~ indazoM-ii;)i mldazo 11,2 -a] pi dd \n\b3~ksr boxa m id : N-(1“(4“matoxi-banzil)~1H-lndazol-4diP7“(2“matDXI·- alaxfllmldazofl ;2~a]pmdln-3-4afboxamld; ld-(14dklobexlbnietib-1H'-lndazob4di)-742-m:8t;oxi-· etoxbiaildazo|1 ^-alpindln-S-karfooxamsd; lem-buííl 3-|(4-{7~<2-öietoxi»atoxi)imidazo{1:?2>a!piriclfr>3~ karboxamidop1H-sr!dazobt-si}mebl)prpendín~1~karboxilát: (R)4e:rC"bubi 3-((447i2''me!oxl-etoxi)lmldazö|i!2-a)p:irki)n''3~ karboxamldo VI H-Indazobl -H )metk)plpeddin~1 -karboxiát; 7~(2-m:atöxi'mtaxiV^V7-((2-aíatsbplri:dia~3-il)miedlV1HHndazob 44!}kaldazaf 1 ^-alpíridin-S-karboxabad ; Mii -(3“(be:nzlloxí)benzilV1Hdndazob44i)-742-m:eloxb eloxllmidazof 1 ;2~a1piddin~3~karboxarnld ; 7-(2~melaxl-atoxiV^47-(4-(tnfluör-rnal|l)benzilV^H''mdazol"4-Ibiaildazöfl J-álpiddin-d-karboxarnid; 7H2"pieloxl-atoxiVN-(l4pMdln~3d!a?atbV1H-mdazQM~ íl)lmldazo|1 J-alpíddia-S-karboxamíd; lerc-balll 4~((4~{7«{2>m8töxb8.tox!)lmicfa2ó{!;2>alpindi^3^ karboxa rnido M Hándaxo I-14l)m ebi (pipe ndka1 "ka* boxllát : tem-buti 24(447V2"rne!oxi--etoxl)imldazo(1í2''alpbldin:"3'' karbexamldo )- 1 H-índazoM d!)raetlí)amrfekne-4-karboxkál; 1 »{{6»metii~pirldín»3H!}meÍI)~1 NMMazol« 4dl)irnldazpf1,2~alpsridín-3~k.arboxamid ; NK 1 -bensői H~indazoir4“îl>T~metoxi-lmidazo!i J-aJpindin-b-kadaoxamid; NK i -óenziM HKndäzöMKf)imidazoi1,2~ a ] p? ri d r n - 3~ka rboxa rnsd ; NK'f ~betóí~1 HdndaxoM'll )~?-®tvxHmi'da.z(1 t2-ajplMm~3~ k&tbùxamM;. NK 1 K(^îraîiidro~2H~piràû“2»il)metil)>i HdadazaMI-il)imid:â20|1 ,2:~ajpiMin4^karboxamid; NK ;2-a}piddiüv3- karboxamid; NK 1 K3Kad roxid>enxd}~1 H-lnd8zoi~4di}-7K2-metoxi~ atoxdiraiciazofl ;;2-'a]pindln~3~karboxamld; 7K2~meîôxi:-et0Xi^NK1Kp*p8ddin~34lmefii>dHdMa2Ol-4-il)i:mÂ20|1,2«a]plndfn»3"ka rbo-xamid ; N~( 1 ~((1; 'aœty-prpfônd:ka3dl)metl>'-1 H4ndazol''4dl)«7»(2“me!oxN etoxi^midazoll^-alpiidin-S-kairfeoxamid; ?K2-fM$oXHStoxi)-NK1 -feniM HdndazoMNpirNidazall,2-a}pi Mi n ~:3·'ka rbox amid; N K14>enzib 5 -b ró m -1 B4nd azo b4 d I )- ? K 2- m etoxi-etoxl^midazofl ,2-a]piMin^karboxamid.; NK1“denal~?Mor-1HHoda2ol~4Ki)~TK2“met:Oxi“ etöxlKr«ídazoí1,2~aJpindin:~3“karboxaniid; NK 1 "beazióó J-dikiof-Ί H-dndazoM"il}~7~(2~meloxi--eta xl ) i-mid azof 12- a j pi rid i n~ 3 ~ka rbo xa mi d ; NK 1 'banzI-S-kléa-l i44ndazQM-ii)“?K2^metaxi* elôN)irnidazo[1>2'-a]pindin''3"karpoxamid; NK1K|d~Í20:propii'-plndsn--2dl)rae:lii)-1H~indazol~4dl>7K2Kó” raadi"piperazin''1 ai}etoxi)irrddazD|1 s2-'a!p!ndin-'3"karboxandd; NK 1 K(1 dzo:propii~5~met!!~ 1 H-pirazof-'3-'ii}p^atsl>1 H4ndazoM~ iiK7K2K4'':metii"piperazsrv1di)etoxi)imidazop:,2“alpin(fin:'-3'' karboxamld: NK 1 '-(S-'metoxabeazli )-1 H and azol-ld) -7K2- aieioxi-6toxÍ|inódazö|1í2~alpsfidin"3'-karböxamld; !^w(iu(3-klôr-b«n2ïi}“1H>indâzoi:~4~il}-?>>{2~:metôxi~ e!Dxíim:kl^:z(){1;:2''a|píndm"3''karfeoxaml£l; ?~(2-metoxS"eloxO"N"( 1 "((6-metikplndira2dl)meti!)-1 Hindazob 4-i}imldâzo|12~aJpifidNv3~k8rboxamici; 7»(2:»metox:i“atox:i}.>N>(1~{3~m0til>befizii)~1H~indazol”4-:ilpnMazöfi.2.~a]p!iidin~3~karfeoxa:rrild; Nil -benzil-1 H4ndazöN4~ilHMluöMmídazöf1 s2”a]plridin>3-karboxamld; Ni' 1 -benziM Hinda2ül~4iíj>«?ii H-plrazol^4-i;l)imidazo|1 ,2-a]plrkiin~3~karboxamíd; 7~aoeiikNi 1 "benzll-l H~indazob44l)ímidazot1 ;2~a|pindm'-3-ikarboxamkl; Nil ^nzil-IH^ndazo^d-IIHií-WdroxbetiOímídaziöil .2-a|pifldin-'3"ka rboxamicl ; Nil -benziM HaadazobdalbTil ~morfokn-elk}lmldazó|1;2~ a'lplddln~3"ka rbaxamid ; 7„|2..:(#»med^psperazln"1"inetoxÍ}~N-(1~((2~met!bt!azob5'- k)met5i)"1 HdndazOí~i-d!knddazo[1 ^-aiP^ddsn^-kafboxamkl; 7i22i~me:ty~píparazki~1“k)6loxi)--N~(1i(6-rTietibplndkv2~ i)m.e|il;)~1H~ifKlazo!”4"iJ)imîdazof1,.2"â]pWdîn>'3~karboxamid.; 722χρβΙοχΗρ!0χΟ'·Ν21'^ί5β!^1:Η~!ί^32θ1~4·'Ι!}ΐπιΐί!ρζο|1ν2'· alpbidi:n--3--karboxamid:; Nil -benzlbl H-iadazol*4ií)-7-cJanö-imídazo|Í 2*®1pindírK3~ kafboxaPdd; Niti>eπzll·1:Handazobidb''^i2ii~metrl·pφeΓazln~i~ !}etexl)i mid axof 1 ;2 '-alpi ndin- 3 - ka rboxa m id ; N'il'-benziM H~Índazoi"4~í:l}-8-€tanoirnidazo(12~a]prídi«-3'“ kad>öxaadd; Ni 1 "benzlbl HNndazoM4l>6~bromimidazo[1: 2~®]P*ddin~3-karboxamid; Nil'-benzJ“1Hindazol~4il)~7i2-m:etoxhetoxl}Ímidazo|tf2·· aipldd-M-kartexamid; Nil "benzíl'i Hdndazö!“iai}~7il ,2“dihidroxi~etil)i.rnldazo|1,2~ a|pi ridirs-3-karbox amid : . N~{1 -benziM H-indazoM~ii)-0~(i,2-çNhidroxi-etiOimidiaxoCI ,2« ="' a]piridire3-karbexamid; N-{1 -benzihl H-indazol«4-ii )~6-meíöxőmidazo[1 s2-ajplridlm3- karboxamid; N3~(1«benzil“1 H-indazoM-iljimidazofi ^-alpiridin-3^6- dlkarboxarnid; N-O-benzihl H-indazob^iiH-brómimidazoll ,2-ajpirídÍn-3- karboxamid: vagy ezeknek egy gyógyászaiiiag elfogadható sója. 1?« Gyógyászati készítmény,, amely az 1-16. igénypontok bármelyike szerinti módon meghatározott t-es képletö vegyüieíeí vagy ennek egy győgyászatuaq elfogadható sóját tartalmazza, valamint egy gyógyászatilag elfogadható oldószert vagy hordozót.18, Az 1-18, igénypontok bármelyike szerinti módon..meghatározott ..... l-es képlete vegyidet vagy ennek egy gyógyászatilag elfogadbátó séta, egy beíegsig vagy rendellenesség kezelésében: váló felhasználás oépta, amely a következők közül választott: ''csontfc^^ógékí-'.iifái'k; autoimmun betegségek, gyulladásos betegségek, szív-érrendszeri betegségek, ftbrózis, fájdalom és daganatok emlősben.
- 19. Az 1. igénypont szerinti vegyiket előállításának folyamata, amely a kővetkezőkből áll: (a) egy megfelelő, íl-es képletö vegyüiet összekapcsolásaahol Z* jelentése COÖH vagy ennek egy reaktív származéka, egy megfelelő. IJf-as képletű vegyülettelkapcsoló reagens jelenlétében; vagy (b) egy megfelelő, IV-es képletű vegyOlef összekapcsolásaegy lll-as képletű vegyülettelegy bázis jelenlétében; vagy (c) az kas képletű vegyOlef képzése céljából, ahol RS jelentése hetCtkl4(1"4C)alkoxt; (heíClkl?>0~ hetClklS(l~4C)alkoxL hkifoxlf l-öCjalkoxt, (tlá:üOf~amtno(1~4C)alköxrvagy alkoxi'^arbonilamidjclifluor(1“4C}alkoxi« egy megfelelő, Y-os képleté vegyülef feagáliatásaahol X\jelentése F fagy Cl, képlétő::t^|yü^ttM, ahol RS* jelentése hefCÍkl%1~4C)alkll~OH, hetCIkl^OH, hefClkl§(1~ ; éCtalklf-OH, p10<1^C)a!fai~OH, siflooramlno(1~4C}alNlhO:H vagy lfi^4G atexpartehIamtó|i^»r|l>4ö)alíeP^:j ''egyenkéríti jelenlétében, ahoi P5 jelentése egy htdrexíl véd^sqportysgy^ (d) az f»es képletei vegyület képzése céljából, ahol Rí5 jelentése : ; : heteiké, ahol hetClkR' jelentése egy nitrogéngyök, egy megfelelő, ¥<# képletü vegyület reagált&iásaegy hetCikf2-H képletö vegyülettek vagy (e) az Pes képfeiü vegyúlet képzése céljából, ahol R5 jelentése heíAPk ahol hetAr4 jelentése egy n!trogéngyök: egy megfelelő, V-s képleté vegyülef reagáltatésaV'~s egy hetAr^-H kèpletu vegyítette?, bázis jelenlétében; vagy (f) az 1-es kèplelü vegyület képzése céljából, ahol Ró jelentése egy szénatomon keresztül kapcsolt szubsztituens a következők közül választva: hetArn helAré és N-{1-3C alkil}píridinon. egy megfelelő, V-b kèpletu vegyület reagáltstásaegy megfelelő, Yt-os képlete vegyölette!ahol Bt ε gyűrő egy szénatom állal kapcsolt gyök a következők közül ; vál^szN'á': ItatAr*, hetAr^ ás M43>ZQ afkltplndlnonll· egyenkébl, pill<lto~kttâÂàtôr:^ á$y öá^iéléftléfében; vagy (§Υφ N* képtetü vigyíJtét képzése céljából, aboli# jelentése hetér4 vagy hétért ahol hetér4 és hetA# feíeeíése széngyök: egy megfelelé, ¥»h képleté vágyóiét reagáltatásaegy hetAr^-H vagy. hetér^-H képlélú vegyöleiél· egyenként, égy 'palládium-katalizátor és egy bázis jelenlétében és adott esetben sgy i iigandum jelenlétében; vagy jh) az has képletü vegyojet képzése céljából· ahol R*> jelentése h@tClk|óc(~0}~, egy megfelelő, Víl-es képletü vegyölet reagáltatásaegy hetCik^-H képietű vegyüíettel, egy kapcsoló reagens jelenlétében;' vagy (í) az kés képietű vegyivel képzése céljából ahol RS szerkezete;egy megfelelő: Vill-as képleté vegyület reagáltatásaahol R-R jelentése vagyegyenként, formaldehiddel egy redukáló ágens jelenlétében; vagy (j) az t-es képletü vegyüiei képzése céljából. ahol R-! jelentése RcRdNC(--O)·'. egy megfelelő.. !X-es képletü vegyüiei reagáitaiásaegy Rï;Rc:NH képletü vegyüieitei egy kapcsoló ágens jelenlétében; vagy (k) az l~es képletü vegyület képzése céljából ahol Rí·5 jelentése egy oxadtazo! szubszttuens, amelynek a képlete;ahol Ff jelentése H vagy Me, egy megfelelő, X-es képleiű vegyülei cfkflaátása :triroetoxi-mátán vagy triatoxi-etán jelenlétében, agyanként; vagy (I) az l-es képletes vegyül«! képzése céljából, ahol RS jelentése 1,3,4-ífaöiazol~2-íi, egy megfelelő: Xl-es képletö vegyület clklizáiásaPgSg jelenlétében; vagy (m) az tes kèpMù vegyület képzése céljából, ahol R5 jelentése : pete-äkä'-'(1"zCa!kii)", anol heítJkia jelentése egy nitrogéngyok, R1--4C : alkoxi)(1-4C alkll)]amlno{1 -2C)a!kû vagy [hidroxK2-4C)aiki!}jammo{1- : : 20)aikli, égy megfelelő. Xft-es képlelö vegyület reagáietásaahol n jelentésé 0 vagy 1 és Z jelentése H vagy káé, égy hetCíkP-H, |(1-4C alköxj)(1-4G alklljjNHg vagy [hidroxi(2-'4C)aM||N:H2:;k!épfetö vegyüleítel. egyenként, egy redukáló ágens jelenlétében; vagy ín) az i-es képlete vegyület képzése céljából! ahol 0: jelentése belAr^CHg- és hetAr2 jelentése egy plrami~gyW, amelynek egy gyűrűben lévő N-atomja egy szphszütuenssel szuhsztlfua!!, a kővetkezők közül választva: vagy (l-óC)aíklk egy megfelelő, XHJ«as képietö vegyület reagèltatàsaeőv í 1 -6C)alkil"X2 képleiü vegyöleftel, egyenként, ahol X2 jelentese egy leváló csoport vagy atom. egy bázis jelenlétében; vagy (ο) az t-e$ képleté vsgyölet képzése céljából, ahol Rí jelenlése Nrt'KsC «ΐΚΐΐ)ρΐΓΗΐίηοηΙΙ''ΟΗ2''! egy megfelelő, XlV-es képletü vegyület kapcsolása(1 "30 atkitbU csoporttal, ahol L1 jelentése egy leváló csoport vagy atom,egy bázis jelenlétében: vagy (p) az i*es képlete vegyület képzése céljából, ahol R& jelentése hetCIkl^CHg", ahol hetCIkP jelentése egy niirogéngyők, egy megfelelő, XV-os képletű vegyület kapcsolásaahol t,k jelentése egy leváló csoport,: egy hetCíkP-H képlete vegyülettel, egy bázis jelenlétében; vagy (gj az i~es képleté vegyület képzése céljából, ahol :Rb jelentése h:etCikl^(1"4C)alkoxl és hetCIkH- jelentése N-metH-piperazin-l ~oxlds egy megfelelő, XVkos képletű vegyület reagáltatásaahol n jelentése 0, 1/ 2 vagy 3/ egy oxidáló ágenssel; vagy (r) az l-es képleté vegyület képzése céljából ahol jelentése :hetClkß(1"4CalkP}" « ahol heiCs.k0 jelentése egy nltrogéngyek, egy megfelelő, XV'lbes képletü vegyület reagálíaiásaahol n jelentése 0, 1, 2 vagy 3 és 1,3 jelentése egyleválé csoport, egy megfelelő, heteiké képtető vegyüleítel, egy bázis jelenlétében; vagy (s) az 1-es képletü vegyület képzése céljából, ahol Ró jelentése (1-40-alkil)C(~Ö)NH(2*4C}alkH4io-s egy megfelelő V~ös képleté vegyület kapcsolásaahoi Xi jelentése F vagy ΟΙ, agy i1«4C a:ikl!)C(-0}HHC2-4C)'alkil~SH képié tű vegyöiettei egy bázis jelenlétében; vagy (t) az Fes képietü vegyulet képzése céljából, ahol RD jelentése CNeCf-OK egy megfelelő, Y~b képlete vegyület kapcsolásaegy vegyüiettei amelynek képlete:egy palládium-katalizátor és egy Ügandum jelenlétében, savval történő kezelést követően: vagy (y) az l~es képieíű vegyiket képzése céljából, ahoi jelentése HÖ{CH2CH2r, egy megfelelő: XYlléas képleté vegyölet kezeléseegy rede káté ágenssel és szükség esetén minden védőcsőéért eltávolítása és szükség esetén ezekből só képzése.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42254710P | 2010-12-13 | 2010-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE025416T2 true HUE025416T2 (hu) | 2016-02-29 |
Family
ID=45478484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11808427A HUE025416T2 (hu) | 2010-12-13 | 2011-12-13 | Szubsztituált n-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-karboxamid vegyületek mint III-as típusú receptor tirozin-kináz inhibitorok |
Country Status (32)
Country | Link |
---|---|
US (3) | US9174981B2 (hu) |
EP (1) | EP2651939B1 (hu) |
JP (3) | JP5868996B2 (hu) |
KR (1) | KR101974665B1 (hu) |
CN (3) | CN103347882B (hu) |
AU (3) | AU2011344001B2 (hu) |
BR (1) | BR112013014854B1 (hu) |
CA (2) | CA2821712C (hu) |
CL (1) | CL2013001712A1 (hu) |
CO (1) | CO6751248A2 (hu) |
CR (1) | CR20130349A (hu) |
DK (1) | DK2651939T3 (hu) |
ES (1) | ES2540996T3 (hu) |
HK (1) | HK1190709A1 (hu) |
HR (1) | HRP20150571T1 (hu) |
HU (1) | HUE025416T2 (hu) |
IL (1) | IL226911A (hu) |
ME (1) | ME02172B (hu) |
MX (1) | MX2013006763A (hu) |
MY (1) | MY172110A (hu) |
NZ (1) | NZ613235A (hu) |
PL (1) | PL2651939T3 (hu) |
PT (1) | PT2651939E (hu) |
RS (1) | RS54070B1 (hu) |
RU (1) | RU2591195C2 (hu) |
SG (1) | SG191129A1 (hu) |
SI (1) | SI2651939T1 (hu) |
SM (1) | SMT201500165B (hu) |
TW (1) | TWI527813B (hu) |
UA (1) | UA112425C2 (hu) |
UY (1) | UY33801A (hu) |
WO (1) | WO2012082689A1 (hu) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ601376A (en) * | 2009-12-21 | 2014-03-28 | Array Biopharma Inc | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
WO2012082689A1 (en) | 2010-12-13 | 2012-06-21 | Array Biopharma Inc. | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN104496891A (zh) * | 2014-12-06 | 2015-04-08 | 哈尔滨工业大学 | 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法 |
CN104974078A (zh) * | 2015-06-25 | 2015-10-14 | 黄荣辉 | 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法 |
KR20180039117A (ko) | 2015-08-11 | 2018-04-17 | 네오메드 인스티튜트 | 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도 |
US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
EP3334719B1 (en) | 2015-08-12 | 2021-09-15 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
EP3371172B1 (en) * | 2015-11-02 | 2021-10-20 | Genase Therapeutics B.V. | Tetrahydroindazoles and medical uses thereof |
CN105198799A (zh) * | 2015-11-03 | 2015-12-30 | 江苏梦得电镀化学品有限公司 | 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法 |
WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
RU2744988C2 (ru) * | 2016-06-14 | 2021-03-17 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
WO2018019291A1 (en) * | 2016-07-29 | 2018-02-01 | The Hong Kong University Of Science And Technology | C(sp3)-c(sp2) cross-coupling reaction of organozinc reagents and heterocyclic (pseudo)halides |
EP3535243B1 (en) | 2016-11-04 | 2021-12-15 | Auckland Uniservices Limited | Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer |
ES2954879T3 (es) * | 2016-11-28 | 2023-11-27 | Eisai R&D Man Co Ltd | Sales de derivado de indazol y cristales de las mismas |
ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
AU2019234670B2 (en) | 2018-03-13 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
CN111410654B (zh) * | 2019-01-19 | 2022-05-17 | 江苏新元素医药科技有限公司 | 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成 |
TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
FI4031547T3 (fi) | 2019-09-18 | 2024-09-16 | Takeda Pharmaceutical Company Ltd | Plasman kallikreiinin estäjiä ja niiden käyttötapoja |
JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
WO2003099811A1 (en) | 2002-05-23 | 2003-12-04 | Cytopia Pty Ltd | Kinase inhibitors |
AU2007337895C1 (en) | 2006-12-22 | 2014-07-31 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
UA101611C2 (ru) * | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
FR2925901B1 (fr) | 2008-01-02 | 2011-03-04 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
JP5502076B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
TW201105669A (en) * | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
NZ601376A (en) * | 2009-12-21 | 2014-03-28 | Array Biopharma Inc | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
WO2012082689A1 (en) * | 2010-12-13 | 2012-06-21 | Array Biopharma Inc. | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
CN102250246A (zh) * | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
-
2011
- 2011-12-13 WO PCT/US2011/064549 patent/WO2012082689A1/en active Application Filing
- 2011-12-13 NZ NZ61323511A patent/NZ613235A/en not_active IP Right Cessation
- 2011-12-13 SG SG2013045349A patent/SG191129A1/en unknown
- 2011-12-13 CN CN201180067342.XA patent/CN103347882B/zh not_active Expired - Fee Related
- 2011-12-13 CA CA2821712A patent/CA2821712C/en not_active Expired - Fee Related
- 2011-12-13 CA CA3027814A patent/CA3027814A1/en not_active Abandoned
- 2011-12-13 RS RS20150446A patent/RS54070B1/en unknown
- 2011-12-13 ME MEP-2015-98A patent/ME02172B/me unknown
- 2011-12-13 SI SI201130508T patent/SI2651939T1/sl unknown
- 2011-12-13 UY UY0001033801A patent/UY33801A/es not_active Application Discontinuation
- 2011-12-13 JP JP2013544674A patent/JP5868996B2/ja not_active Expired - Fee Related
- 2011-12-13 RU RU2013132758/04A patent/RU2591195C2/ru active
- 2011-12-13 TW TW100146108A patent/TWI527813B/zh not_active IP Right Cessation
- 2011-12-13 PL PL11808427T patent/PL2651939T3/pl unknown
- 2011-12-13 CN CN201811311712.XA patent/CN109608449A/zh active Pending
- 2011-12-13 MX MX2013006763A patent/MX2013006763A/es active IP Right Grant
- 2011-12-13 BR BR112013014854-3A patent/BR112013014854B1/pt not_active IP Right Cessation
- 2011-12-13 EP EP11808427.6A patent/EP2651939B1/en active Active
- 2011-12-13 UA UAA201308896A patent/UA112425C2/uk unknown
- 2011-12-13 US US13/994,048 patent/US9174981B2/en not_active Expired - Fee Related
- 2011-12-13 ES ES11808427.6T patent/ES2540996T3/es active Active
- 2011-12-13 KR KR1020137018492A patent/KR101974665B1/ko active IP Right Grant
- 2011-12-13 CN CN201610248287.9A patent/CN105924437B/zh not_active Expired - Fee Related
- 2011-12-13 AU AU2011344001A patent/AU2011344001B2/en not_active Ceased
- 2011-12-13 PT PT118084276T patent/PT2651939E/pt unknown
- 2011-12-13 MY MYPI2013700991A patent/MY172110A/en unknown
- 2011-12-13 DK DK11808427.6T patent/DK2651939T3/en active
- 2011-12-13 HU HUE11808427A patent/HUE025416T2/hu unknown
-
2013
- 2013-06-13 IL IL226911A patent/IL226911A/en active IP Right Grant
- 2013-06-13 CL CL2013001712A patent/CL2013001712A1/es unknown
- 2013-07-15 CO CO13167580A patent/CO6751248A2/es active IP Right Grant
- 2013-07-15 CR CR20130349A patent/CR20130349A/es unknown
-
2014
- 2014-04-22 HK HK14103774.0A patent/HK1190709A1/xx not_active IP Right Cessation
-
2015
- 2015-05-28 HR HRP20150571TT patent/HRP20150571T1/hr unknown
- 2015-07-08 SM SM201500165T patent/SMT201500165B/xx unknown
- 2015-09-18 US US14/858,029 patent/US9809590B2/en not_active Expired - Fee Related
- 2015-10-19 JP JP2015205806A patent/JP2016040303A/ja not_active Withdrawn
-
2016
- 2016-09-02 AU AU2016222468A patent/AU2016222468B2/en not_active Ceased
-
2017
- 2017-09-27 US US15/717,700 patent/US10669269B2/en not_active Expired - Fee Related
- 2017-11-27 JP JP2017227134A patent/JP2018065835A/ja not_active Withdrawn
-
2018
- 2018-03-16 AU AU2018201903A patent/AU2018201903B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018201903B2 (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | |
KR101779630B1 (ko) | cFMS 억제제로서 치환된 N-(1H-인다졸-4-일)이미다조[1,2-a]피리딘-3-카복사미드 화합물 | |
AU2011344001A1 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
KR101659193B1 (ko) | Btk 활성의 억제제로서의 헤테로아릴 피리돈 및 아자-피리돈 화합물 |